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Executive summary 
Introduction 
Health Problem 
This systematic review is focussed on patients with articular cartilage defects. 
Articular cartilage, which covers the ends of bones, decreases friction and pro-
vides cushioning in joints. Defects in articular cartilage and subchondral bone 
can be caused by trauma, cancer, or other arthropathies. Osteochondral de-
fects increase in friction in joints, which can lead to inflammation, swelling, 
pain and stiffness. 
Description of Technology 
In theory, osteochondral allograft transplantation (OCA) can be used to treat 
chondral and osteochondral defects of all sizes, locations and contours; how-
ever, it is generally indicated for the treatment of lesions greater than 2cm2, 
and failing conservative management or first-line surgical treatment. It has 
been mainly used to treat the knee joint but has also been used to treat the 
ankle, shoulder and elbow. In the absence of OCA, other surgical procedures 
such as osteochondral autologous transplantation, mosaicplasty, and micro-
fracture may be considered, depending on the size and location of the defect. 
Research question 
Is osteochondral allograft transplantation for the knee or other joints, in com-
parison to other surgical management, in patients with osteochondral defects, 
more effective and safe concerning pain, function, quality of life, implant fail-
ure and adverse events? 
 
Methods 
A systematic review was conducted to investigate the safety and effectiveness 
of OCA. Four biomedical databases (Medline, Embase, the Cochrane Library, 
the University of York Centre for Reviews and Dissemination) were searched 
from inception to 12 December 2018. At least two authors independently 
conducted the study selection (TV, KR), data extraction (TV, KR, DS), and 
quality appraisal (TV, KR, DS). Only prospective studies with at least two 
years of follow-up were considered for inclusion. 
Domain effectiveness 
Critical outcomes used to evaluate the relative efficacy of OCA included 
changes in pain scores (e.g. KOOS-Pain, VAS, WOMAC-Pain), changes in 
disease-specific function scores (e.g. IKDC, WOMAC, KOOS), quality of 
life, and the necessity for joint replacement. 
Domain safety 
Critical outcomes used to evaluate the relative safety of OCA included pro-
cedure-related mortality, adverse events, and transplant failure rates. 
 
focus on patients  
with articular cartilage 
defects 
osteochondral allograft 
transplantation (OCA) 
to treat (osteo)chondral 
defects in the knee and 
other joints (ankle, 
shoulder, elbow) 
osteochondral allograft 
transplantation more 
effective and safe? 
literature search in 
databases, selection, 
extraction and quality 
appraisal by at least  
two authors 
pain, function, quality 
of life and necessity for 
joint replacement for 
effectiveness 
mortality, complications 
and transplant failure 
for safety 
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Results 
Available evidence 
One randomised controlled trial (RCT) was identified (n=40), which inves-
tigated OCA to treat ankle defects. In addition, one case series investigating 
ankle defects (n=16), included for the assessment of safety only, and four 
case series investigating knee defects (n=165) were identified. No relevant 
evidence was identified for other joints. 
Clinical effectiveness 
There was no difference in pain reported across groups in the RCT compar-
ing ankle OCA to autologous grafting (p=0.15). Pain was measured using three 
different scales in the case series studies on knee OCA, which all showed a 
statistically significant reduction between pre-operative and post-operative 
scores. The quality of evidence for this outcome was very low. 
Function increased in both ankle OCA and autologous ankle transplant groups 
in the RCT (n=40), with no significant difference reported between groups 
(p=0.25). Knee OCA was reported using a range of scales, including IKDC, 
WOMAC (function), WOMAC (overall), modified Cincinnati knee-rating 
score (function), and modified Cincinnati knee-rating score (function). All 
of the included case series reported statistically significant improvements in 
function between pre-operative and post-operative scores. The quality of ev-
idence for this outcome was very low. 
Quality of life was not reported for ankle OCA. Improvements were reported 
by two case series on knee OCA, which demonstrated statistically significant 
improvements between pre- and post-operative KOOS (QoL) scores at 2-years 
follow-up (p<0.001). The quality of evidence for this outcome was very low. 
Necessity of total joint replacement was not reported for ankle OCA. Two case 
series on knee OCA reported progression to arthroplasty, of 3.0% (1/34) over 
2 years, and 6.6% (6/91) over a mean of 5.7 years, respectively. The data were 
too limited to draw meaningful conclusions for this outcome. 
Safety 
No procedure-related mortality was reported in any of the included studies for 
knee and ankle. 
Complication rates were reported variably across the included studies. The 
RCT (n=40) reported no difference between ankle OCA and autologous trans-
plant (RR=0.93, 95% CI 0.24 to 5.60). Reported complications for knee OCA 
ranged from 4.3% to 26.5%. The most common complications included frag-
mentation of delamination of the graft, fraying, and stiffness requiring ma-
nipulation. The quality of evidence for this outcome was very low. 
The relative failure rate for ankle OCA was higher compared to autologous 
grafts (RR = 1.25, 95% CI 0.20 to 7.92), as reported in one RCT (n=40) with 
two years of follow-up; however, this study lacked power to detect a signifi-
cant difference. Failure rates for ankle OCA ranged from 12.5% over 2 years, 
to 29.4% over a mean of 4.1 years. Failure rates were lower for knee OCA, 
ranging between 7.0% to 11.8% over 2 years. The quality of evidence for this 
outcome was very low. 
1 RCT (n=40) and  
1 case series (n=16)  
for ankle joint 
 
4 case series (n=165)  
for knee joint 
pain:  
ankle – no difference 
between groups;  
knee – significant  
better reduction 
function: ankle – 
increase in groups;  
knee – improvements 
between pre- &  
post-operative scores 
quality of life:  
knee – improvements 
between pre- &  
post-operative scores 
joint replacement:  
knee – 3.0-6.6% in  
2 case series 
mortality: not reported 
complications:  
ankle – no difference 
between groups;  
knee – 4.3-26.5% across 
studies 
failure rate:  
ankle – higher for OCA 
compared to autologous 
grafts (RCT),  
absolute failure rates 
ranged from 12.5-29.4%; 
knee – 7.0-11.8% 
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Upcoming evidence 
There is only one ongoing clinical trial of OCA, which is a single-arm trial 
with an estimated enrolment of 50 patients and completion date of April 2020. 
As such, there are currently no ongoing trials that are likely to influence a 
decision on OCA in the near future. 
Reimbursement 
Currently, OCA is not reimbursed by the Austrian health care system for 
treating osteochondral defects in articular cartilage. 
 
Discussion 
There is a paucity of rigorous, prospective data investigating OCA for treat-
ing osteochondral defects. The overall quality of the evidence that was avail-
able for ankle and knee indications was low or very low for the reported out-
comes. 
The main limitations in the evidence base were related to small sample sizes, 
a lack of comparative data, and short follow-up durations. Although a mini-
mum of 24 months was set as inclusion criteria in this review, long-term 
outcomes such as graft failure require a minimum of four years follow-up to 
evaluate. None of the available evidence met this criterion. In addition, the 
only available RCT had a high risk of bias due to inadequate allocation con-
cealment, randomisation and blinding. 
 
Recommendation 
The current evidence is not sufficient to prove that OCA for the knee and 
other joints, for the treatment of osteochondral defects, is more effective and 
equally safe than other surgical procedures. Furthermore, the prospective 
single-arm studies had insufficient power to demonstrate treatment efficacy. 
Based on available evidence, inclusion in the hospital benefit catalogue is 
not recommended at this time. 
  
only 1 ongoing  
single-arm trial 
OCA not reimbursed  
in Austria 
low or very low quality 
of evidence 
evidence base as  
main limitation, only  
1 RCT with high risk  
of bias included 
evidence not sufficient 
 
OCA not recommended 
for reimbursement 
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Zusammenfassung 
Einleitung 
Indikation und therapeutisches Ziel 
Die vorliegende systematische Übersichtsarbeit konzentrierte sich auf Pati-
entInnen mit Gelenkknorpeldefekten. Gelenkknorpel bedecken die Enden 
der Knochen und verringern somit die Reibung bzw. sorgen für die Dämp-
fung der Gelenke. Defekte im Gelenkknorpel und im subchondralen Kno-
chen können durch Traumata, Krebs oder andere Arthropathien verursacht 
werden. Osteochondrale Defekte erhöhen die Reibung in den Gelenken, was 
zu Entzündungen, Schwellungen, Schmerzen und Steifheit führen kann. 
Beschreibung der Technologie 
Grundsätzlich kann die osteochondrale Allograft Transplantation (OCA) ver-
wendet werden, um chondrale und osteochondrale Defekte jeder Größe, Po-
sition und Umgebung zu behandeln. Im Speziellen ist die OCA jedoch für 
die Behandlung von Läsionen, die größer als 2 cm2 sind und nach einem Ver-
sagen der konservativen Behandlung oder der chirurgischen Erstlinienbe-
handlung indiziert. Die OCA wird hauptsächlich zur Behandlung des Knie-
gelenks, sowie des Knöchel-, Schulter- und Ellbogengelenks eingesetzt. Ist 
eine OCA nicht indiziert, können abhängig von der Größe und der Lokalisa-
tion des Defekts andere chirurgische Verfahren wie osteochondrale autologe 
Transplantation, Mosaikplastik und Mikrofrakturierung in Betracht gezogen 
werden. 
Wissenschaftliche Fragestellung 
Ist bei PatientInnen mit osteochondralen Defekten eine osteochondrale Al-
lograft Transplantation für das Knie oder andere Gelenke im Vergleich zu 
anderen chirurgischen Maßnahmen wirksamer in Bezug auf Schmerzen, 
Funktion (der Gelenke), Lebensqualität und der Notwendigkeit eines Gelen-
kersatzes und sicherer im Hinblick auf unerwünschte Ereignisse? 
 
Methoden 
Zur Beantwortung der Forschungsfrage wurde am 12. Dezember 2018 eine 
systematische Literatursuche in vier Datenbanken durchgeführt: 
 Medline, 
 Embase, 
 Cochrane Library, 
 University of York Center for Reviews und Dissemination. 
Mindestens zwei AutorInnen führten unabhängig voneinander die Studien-
auswahl (TV, KR), Datenextraktion (TV, KR, DS) und Qualitätsbewertung 
(TV, KR, DS) durch. Nur prospektive Studien mit einer Nachbeobachtungs-
zeit von mindestens zwei Jahren wurden in Betracht gezogen. 
 
Fokus auf  
PatientInnen mit 
Gelenkknorpeldefekten 
osteochondrale Allograft 
Transplantation (OCA) 
zur Behandlung von 
(osteo)chondralen 
Defekten im Knie und 
anderen Gelenken 
(Knöchel, Schulter, 
Ellbogen) 
Forschungsfrage 
Literatursuche  
in Datenbanken, 
Selektion, Extraktion 
und Qualitätsbewertung 
von mindestens  
2 AutorInnen 
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Klinische Wirksamkeit 
Die kritischen Endpunkte, die als Basis für die Bewertung der Wirksamkeit 
von OCA herangezogen wurden, umfassten: 
 Veränderungen der Schmerzwerte  
(z. B. mittels KOOS-Pain, VAS, WOMAC-Pain), 
 Veränderungen der krankheitsspezifischen Funktion des Kniegelenks 
bzw. anderer Gelenke (z. B. mittels IKDC, WOMAC, KOOS), 
 Lebensqualität und 
 Notwendigkeit eines Gelenkersatzes. 
Sicherheit 
Die Endpunkte, die für die Ableitung einer Empfehlung zur Sicherheit der 
OCA herangezogen wurden, umfassten: 
 interventionsbedingte Mortalität, 
 unerwünschte Ereignisse und 
 Versagen des Transplantats. 
 
Ergebnisse 
Verfügbare Evidenz 
Zur Bewertung der Wirksamkeit konnte lediglich eine randomisierte kontrol-
lierte Studie (RCT) mit 40 PatientInnen identifiziert werden, die die OCA im 
Vergleich zur autologen Transplantation für die Behandlung von Sprungge-
lenksdefekten untersuchte. 
Darüber hinaus konnten eine prospektive Fallserie zur Untersuchung von 
Sprunggelenksdefekten (n=16) und vier prospektive Fallserien, die Kniede-
fekte (n=165) untersuchten, für die Bewertung der Sicherheit identifiziert 
werden, die den Einschlusskriterien des vorliegenden Berichts entsprachen. 
Es konnte keine relevante Evidenz für andere Gelenke identifiziert werden. 
Für prospektive Studien wurde ein Nachbeobachtungszeitraum von mindes-
tens zwei Jahren als Einschlusskriterium festgelegt. 
Klinische Wirksamkeit 
Es wurde kein Unterschied in der Veränderung der Schmerzwerte im RCT be-
richtet, bei denen die OCA am Sprunggelenk mit der autologen Transplan-
tation verglichen wurde (p=0.15). Die Veränderung der Schmerzwerte wurde 
anhand von drei verschiedenen Skalen in den Fallserien zur Knie-OCA ge-
messen, die alle eine statistisch signifikante Reduktion zwischen präoperati-
ven und postoperativen Scores zeigten. Die Qualität der Evidenz für dieses 
Ergebnis war sehr gering. 
Die krankheitsspezifische Funktionalität erhöhte sich im RCT (n=40) sowohl in 
der OCA-Gruppe als auch in der autologen Transplantationsgruppe, wobei 
zwischen den Gruppen kein signifikanter Unterschied berichtet wurde (p= 
0.25). In den Fallserien für das Kniegelenk wurde der Endpunkt anhand ei-
ner Reihe von Skalen gemessen, einschließlich IKDC, WOMAC (Funktion), 
WOMAC (Gesamt), modifizierter Cincinnati-Kniebewertung (Funktion) und 
modifizierter Cincinnati Kniebewertungs-Score (Funktion). Alle eingeschlos-
senen Fallserien berichteten über statistisch signifikante Funktionsverbesse-
rungen zwischen präoperativen und postoperativen Scores. Die Qualität der 
Evidenz für dieses Ergebnis war sehr gering. 
entscheidende 
Endpunkte für 
Wirksamkeit ... 
... und Sicherheit 
1 RCT (n=40)  
für Sprunggelenk 
zusätzlich:  
1 Fallserie (n=16)  
für Sprunggelenk und  
4 Fallserien (n=165)  
für Kniegelenk 
Schmerzen: 
Sprunggelenk – kein 
Unterschied zwischen 
den Gruppen;  
Knie – deutlich  
größere Reduktion 
Funktionalität: 
Sprunggelenk – 
Verbesserung in  
beiden Gruppen;  
Knie – Verbesserungen 
zwischen prä- und 
postoperativen Scores 
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Die Lebensqualität wurde im RCT für Sprunggelenks-OCA nicht berichtet. 
Verbesserungen in der Lebensqualität wurden in zwei Fallserien zum Knie-
gelenk berichtet, die statistisch signifikante Verbesserungen zwischen den 
prä- und postoperativen KOOS-Werten (QoL) nach einer 2-Jahres Nachbe-
obachtungszeit zeigten (p<0.001). Die Qualität der Evidenz für dieses Er-
gebnis war sehr gering. 
Die Notwendigkeit eines vollständigen Gelenkersatzes wurde im RCT für Sprung-
gelenks-OCA nicht berichtet. In zwei Fallserien zum Kniegelenk wurde über 
einen Zeitraum von 2 Jahren ein Fortschreiten der Arthroplastik von 3.0 % 
(1/34) bzw. 6.6 % (6/91) über einen Zeitraum von 5.7 Jahren berichtet. Die 
Daten waren allerdings zu limitiert, um aussagekräftige Schlussfolgerungen 
für diesen Endpunkt ziehen zu können. 
Sicherheit 
In keiner der eingeschlossenen Studien für das Knie- und Sprunggelenk 
wurde von einer interventionsbedingten Mortalität berichtet. 
Unerwünschte Ereignisse wurden in den eingeschlossenen Studien unterschied-
lich berichtet. Das RCT für das Sprunggelenk (n=40) identifizierte keinen 
Unterschied zwischen der OCA und der autologen Transplantation (RR=0.93, 
95 % CI 0.24 bis 5.60). Die berichteten unerwünschten Ereignisse für das 
Kniegelenk lagen zwischen 4.3 % und 26.5 %. Zu den häufigsten Komplika-
tionen zählte die Fragmentierung der Delamination des Transplantats, die 
Auffaserung sowie Versteifungen, die Bewegung erfordern. Die Qualität der 
Evidenz für diesen Endpunkt war sehr gering. 
Das relative Versagen des Transplantats wurde im RCT (n=40) für das Sprung-
gelenk berichtet und war nach zweijähriger Nachbeobachtungszeit für die 
OCA im Vergleich zur autologen Transplantation höher (RR=1,25, 95 % CI 
0,20 bis 7,92). Diese Studie war jedoch nicht ausreichend gepowert, um einen 
statistisch signifikanten Unterschied feststellen zu können. Das Versagen 
des Transplantats für die Sprunggelenks-OCA lag bei 12.5 % über 2 Jahre 
und bei 29.4 % über einen Zeitraum von 4.1 Jahren. Die Versagensraten der 
Transplantate in den Fallserien für die Kniegelenks-OCA waren niedriger 
und lagen bei einer Nachbeobachtungszeit von 7 Jahren zwischen 7.0 % und 
11.8 %. Die Qualität der Evidenz für diesen Endpunkt war sehr gering. 
Laufende Studien 
Aktuell ist nur eine laufende Studie registriert, die die OCA bei osteochond-
ralen Defekten im Kniegelenk untersucht. Es handelt sich dabei um eine 
unkontrollierte Fallserie mit einer geschätzten Anzahl von 50 PatientInnen 
und Abschlussdatum im April 2020. Daher gibt es derzeit keine laufenden 
relevanten Studien, die neue Erkenntnisse bezüglich der Wirksamkeit der 
OCA im Vergleich zu anderen chirurgischen Verfahren liefern werden. 
Kostenerstattung 
Derzeit erfolgt keine Kostenerstattung der OCA zur Behandlung von osteo-
chondralen Gelenksknorpeldefekten durch das öffentliche österreichische 
Gesundheitssystem. 
 
 
Lebensqualität:  
Knie – Verbesserungen 
zwischen prä- und 
postoperativen Scores 
Gelenkersatz:  
Knie – 3.0-6.6 % in  
2 Fallserien 
Mortalität:  
nicht berichtet 
Komplikationen: 
Sprunggelenk – kein 
Unterschied zwischen 
den Gruppen;  
Knie – 4.3-26.5 % über 
Studien hinweg 
Versagensrate: 
Sprunggelenk – höhere 
OCA-Werte im Vergleich 
zu autologer 
Transplantation (RCT); 
absolute Versagensrate 
zwischen  
12.5 und 29.4 %; 
Knie – 7.0-11.8 % 
lediglich eine laufende 
prospektive Fallserie 
derzeit keine 
Kostenerstattung 
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Diskussion 
Es gibt einen Mangel an exakten, prospektiven Daten, die die OCA zur Be-
handlung von osteochondralen Defekten untersuchen. Insgesamt war die Qua-
lität und Stärke der Evidenz, die für die Beantwortung der Forschungsfrage 
und für die Indikationen Sprunggelenk und Knie identifiziert wurde, gering 
oder sehr niedrig. 
Die Schwächen der Evidenz lagen vor allem im Design der Studien (z. B. 
handelte es sich Großteils um Fallserien), in den kleinen Stichprobengrößen, 
fehlender Vergleichsdaten und den kurzen Nachbeobachtungszeiträumen. 
Obwohl für die vorliegende systematische Übersichtsarbeit ein Minimum 
von 24 Monaten Nachbeobachtungszeitraum als Einschlusskriterium festge-
legt wurde, ist für die Beurteilung langfristiger Ergebnisse wie Transplantat-
versagen ein Nachbeobachtungszeitraum von mindestens vier Jahren erfor-
derlich. Keine der eingeschlossenen Studien erfüllte dieses Kriterium. Dar-
über hinaus hatte das einzige verfügbare RCT ein hohes Bias-Risiko auf-
grund unzureichender Randomisierung, Allocation Concealment und Ver-
blindung. 
 
Empfehlung 
Auf der Grundlage der verfügbaren Evidenz können keine Schlussfolgerungen 
gezogen werden, ob das bewertete Verfahren der OCA zur Behandlung von 
osteochondralen Defekten im Knie oder anderen Gelenken wirksamer und 
gleichermaßen sicher ist wie andere chirurgische Verfahren. Darüber hinaus 
hatten die prospektiven einarmigen Studien keine ausreichende Qualität (me-
thodische Mängel), um die Wirksamkeit des Verfahrens nachzuweisen. Auf 
Basis der verfügbaren Evidenz und in Ermangelung an adäquaten laufenden 
Studien, wird die Aufnahme in den Erstattungskatalog nicht empfohlen. 
 
geringe bis sehr geringe 
Evidenzstärke 
Schwächen der Evidenz: 
Studiendesign, fehlende 
Vergleichsdaten, kleine 
Stichprobengrößen 
 
lediglich 1 RCT mit 
hohem Bias-Risiko 
identifiziert 
Evidenz unzureichend 
 Aufnahme nicht 
empfohlen 
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1 Scope 
1.1 PICO question 
Is osteochondral allograft transplantation for the knee and other joints in 
comparison to other surgical management in patients with osteochondral de-
fects more effective and safe concerning pain, function, quality of life, im-
plant failure and adverse events? 
 
 
1.2 Inclusion criteria 
Inclusion criteria for relevant studies are summarized in Table 1-1. 
Table 1-1: Inclusion criteria 
Population  Patients with osteochondral defects in articular cartilage of the knee or other joint who 
have failed conservative management or primary surgery. 
 International classification of diseases (ICD)-10-CM code: M94.8 Other specified 
disorders of cartilage 
 Contraindications/exclusions: Instability/misalignment of knee joint, late-stage 
osteoarthritis, rheumatoid disease, multiple cartilage defects, osteonecrosis, tumours 
 MeSH Terms: Cartilage, Articular/injuries* 
Intervention  Fresh or delayed-fresh osteochondral allograft transplantation (OCA) 
 Product names: Not applicable 
 MeSH Term: Cartilage/transplantation*, Chondrocytes/transplantation, Allografts 
Control  Surgical management; including but not limited to autologous chondrocyte 
implantation, osteochondral grafting, and microfracture. 
 MeSH Terms: Not applicable (not used for the search strategy) 
Rationale: The primary aim of OCA is to improve symptoms of cartilage defects, and to 
prevent or delay the progression to osteoarthritis and total or partial knee arthroplasty. In 
this context, patients typically must have failed conservative management to qualify for 
OCA, therefore the main comparators are other surgical cartilage regeneration or repair 
procedures. 
Outcomes  
Efficacy Clinical endpoints include changes from pre- to post-treatment measurements of: 
 Decrease in pain, including but not limited to: 
 Visual analogue scale (VAS) 
 Lysholm Score 
 International Knee Documentation Committee (IKDC) 
 Knee Society Knee Score 
 Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
 Increase in functionality, including but not limited to: 
 Lysholm Score 
 Tegner activity grading scale 
 Knee injury and Osteoarthritis Outcome Score (KOOS) 
 Knee Society Function Score 
 IKDC 
 WOMAC 
 
PIKO-Frage 
Einschlusskriterien  
für relevante Studien 
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Outcomes/Efficacy 
(continuation) 
 Increase in quality of life (QoL), including but not limited to: 
 36-item Short Form Health Survey Questionnaire (SF-36) 
 Dartmouth Cooperative Functional Assessment Charts (COOP) 
 Necessity of total joint replacement 
 Return to daily/sports/physical activities 
Rationale: Appropriate clinical outcomes have been informed  
by systematic reviews [1,2], and the EUnetHTA guidelines [3]. 
Safety Relevant safety outcomes include (critical outcomes are highlighted in bold): 
 Procedure-related mortality 
 Adverse events (peri- and post-operative) 
 Transplant failure rates 
 Re-admission 
 Re-operation/additional surgery 
Rationale: Appropriate safety outcomes have been informed  
by recent systematic reviews [1,2], and the EUnetHTA guidelines [4]. 
Study design  
Efficacy  Randomised controlled trials 
 Prospective non-randomised comparative study designs 
 In the absence of comparative evidence, prospective case series with ≥ 15 patients 
and at least 24 months follow-up will be included.  
Excluded: conference abstracts, narrative reviews, letter to the editor,  
author response, case reports, retrospective comparative studies, animal studies, 
cadaveric studies 
Safety  Randomised controlled trials 
 Prospective non-randomised controlled trials 
 Prospective case-series with ≥ 15 patients and 24 months follow-up 
Excluded: conference abstracts, narrative reviews, letter to the editor, author 
response, case reports, retrospective case series, animal studies, cadaveric studies 
Abbreviations: COOP = Dartmouth Cooperative Functional Assessment Charts; ICD = International Statistical Classification 
of Diseases; IKDC = International Knee Documentation Committee; KOOS = Knee injury and Osteoarthritis Outcome Score; 
SF-36 = 36-item Short Form Health Survey Questionnaire; VAS = Visual analogue scale; WOMAC = Western Ontario and 
McMaster Universities Osteoarthritis Index 
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2 Methods 
2.1 Research questions 
Description of the technology 
Element ID Research question 
B0001 What are osteochondral allograft transplantation and the comparator(s)? 
A0020 For which indications has osteochondral allograft transplantation received  
marketing authorisation or CE marking? 
B0002 What is the claimed benefit of osteochondral allograft transplantation in relation  
to other surgical procedures? 
B0003 What is the phase of development and implementation of osteochondral allograft 
transplantation and other surgical procedures? 
B0004 Who administers osteochondral allograft transplantation and other surgical procedures  
and in what context and level of care are they provided? 
B0008 What kind of special premises are needed to use osteochondral allograft transplantation  
and other surgical procedures? 
B0009 What supplies are needed to use osteochondral allograft transplantation  
and other surgical procedures? 
A0021 What is the reimbursement status of osteochondral allograft transplantation? 
 
Health problem and current use 
Element ID Research question 
A0001 For which health conditions, and for what purposes is osteochondral allograft  
transplantation used? 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for ostoechondral defects? 
A0004 What is the natural course of ostoechondral defects? 
A0005 What is the burden of disease for the patients with ostoechondral defects? 
A0006 What are the societal consequences of ostoechondral defects? 
A0024 How are osteochondral defects currently diagnosed according to published guidelines  
and in practice? 
A0025 How are osteochondral defects currently managed according to published guidelines  
and in practice? 
A0007 What is the target population in this assessment?  
A0023 How many people belong to the target population? 
A0011 How much is ostehchondral allograft transplantation utilised? 
 
Clinical effectiveness 
Element ID Research question 
D0001 What is the expected beneficial effect of osteochondral allograft transplantation on mortality? 
A0003 What is the effect of osteochondral allograft transplantation on the mortality  
due to causes other than osteochondral defects? 
D0005 How does osteochondral allograft transplantation affect symptoms and findings  
(severity, frequency) of osteochondral defects? 
D0006 How does osteochondral allograft transplantation affect progression (or recurrence)  
of the disease or health condition? 
Osteochondral allograft transplantation for the knee (or other joints) 
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Clinical effectiveness 
Element ID Research question 
D0011 What is the effect of osteochondral allograft transplantation on patients’ body functions? 
D0016 How does the use of osteochondral allograft transplantation affect activities of daily living? 
D0012 What is the effect of osteochondral allograft transplantation on generic health-related  
quality of life? 
D0013 What is the effect of osteochondral allograft transplantation on disease-specific quality of life? 
D0017 Was the use of osteochondral allograft transplantation worthwhile? 
 
Safety 
Element ID Research question 
C0008 How safe is osteochondral allograft transplantation in comparison to the comparator(s)? 
C0002 Are there harms related to dosage or frequency of applying osteochondral allograft 
transplantation? 
C0004 How does the frequency or severity of harms change over time or in different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use of 
osteochondral allograft transplantation? 
C0007 Are osteochondral allograft transplantation and other surgical procedures associated with 
user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of osteochondral 
allograft transplantation and other surgical procedures? 
 
 
2.2 Sources 
A range of sources were used to identify relevant literature to answer the re-
search questions relating to the description of the technology, health prob-
lem and current use, including: 
Description of the technology 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospitals  
Health problem and Current Use 
 Handsearch in the POP, AdHopHTA and CRD databases  
for Health Technology Assessments 
 Handsearch of clinical guideline databases (AHRQ, EBM guidelines) 
 Background publications identified in database search: see Section 2.3 
 Questionnaire completed by the submitting hospitals  
 
 
Quellen:  
systematische Suche, 
Handsuche sowie 
Informationen der 
Hersteller und 
Einreicher 
Methods 
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2.3 Systematic literature search 
The systematic literature search was conducted on the 12th of December 2018 
in the following databases:  
 Medline via Ovid (including PubMed) 
 Embase  
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA) 
The systematic search was limited to articles published in English or Ger-
man; no other limits were applied to the search strategy. The specific search 
strategy employed can be found in the Appendix. 
Furthermore, to identify ongoing and unpublished studies, a search in three 
clinical trials registries (ClinicalTrials.gov; WHO-ICTRP; EU Clinical Tri-
als) was conducted on the 11th of January 2019, resulting in 75 potentially 
relevant hits. Of those, 3 may be considered relevant (observational studies) 
and are included in the Appendix (see Chapter “List of ongoing trials”). 
The submitting hospital provided eight publications, all of which were iden-
tified in the database searches. 
The database searches were supplemented by hand-searches and pearling of 
identified studies, which resulted in 16 potentially relevant studies. 
 
 
2.4 Flow chart of study selection 
Overall 744 citations were identified through the database searches, and 16 
additional citations were identified through targeted handsearching and pearl-
ing of identified studies. After deduplication, 582 citations were identified 
for screening by title and abstract. The references were screened by two in-
dependent researchers (TV, KR) and cases of disagreement were resolved 
through discussion. The selection process is displayed in Figure 2-1. 
Relevant studies with appropriate study designs were identified for knee and 
ankle indications only. No relevant evidence was identified for other joints 
that may be considered for OCA, such as hips and shoulders. 
In total, one RCT and one case series were included for ankle indications, 
and four case series were included for knee indications. For ankle indications, 
only the RCT was included for effectiveness outcomes, as this represents the 
highest level of evidence. Both the RCT and case series were included for safe-
ty outcomes. 
systematische 
Literatursuche in  
4 Datenbanken 
Suche eingegrenzt  
nach Sprache 
Suche nach laufenden 
Studien: 3 Treffer 
zusätzliche Literatur 
von Einreicher & durch 
Handsuche 
Literaturauswahl: 
insgesamt  
582 Publikationen 
identifiziert 
lediglich Studien zum 
Knie- & Sprunggelenk 
identifiziert 
6 Studien 
eingeschlossen 
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Figure 2-1: Flow chart of study selection (PRISMA Flow Diagram) 
 
2.5 Analysis 
Due to the paucity of available evidence, and limited study designs, the safety 
and effectiveness results are reported narratively. Two independent research-
ers conducted quality appraisal, including risk of bias assessment, with dif-
ferences settled via consensus. Quality appraisal was conducted with differ-
ent tools presented in the Appendix, depending on study design (see Appen-
dix Table A-3 and Table A-4). Randomised controlled trials were appraised 
using the Cochrane RoB tool Version 2.0 [5]. Single arm case series were eval-
uated using the Institute of Health Economics (IHE) checklist [6]. 
 
 
2.6 Synthesis 
The questions were answered in plain text format with reference to Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) 
evidence tables that are included in Appendix, results were summarized in 
Table 7-1 and Table 7-2. No quantitative analysis of outcomes was performed, 
due limited number of relevant comparative trials identified. 
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 Additional records identified 
through other sources  
(n=16) 
Records after duplicates  
removed 
(n=582) 
Records screened 
(n=582) 
Records excluded 
(n=516) 
Full-text articles  
assessed for eligibility 
(n=66) Full-text articles excluded,  
with reasons 
(n=60) 
 Other intervention (n=3) 
 Duplicate sample (n=1) 
 Conference abstract (n=8) 
 Retrospective study (n=36) 
 Sample size <15 (n=5) 
 Follow-up <24 months (n=1) 
 Background literature (n=6) 
Studies included in qualitative 
synthesis 
(n=6) 
 RCT, ankle (n=1) 
 Case-series, knee (n=4) 
 Case-series, ankle (n=1) 
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3 Description and technical 
characteristics of technology 
Features of the technology and comparators 
B0001 – What are osteochondral allograft transplantation  
and the comparator(s)? 
Hyaline cartilage is found in the articular surfaces of bones, where they form 
joints. Often referred to as articular cartilage, it decreases friction and ena-
bles bones to glide smoothly over each other [7]. 
Fresh or delayed-fresh osteochondral allograft transplantation (OCA) is a 
technique used to repair both chondral defects (those in which only the artic-
ular cartilage is damaged) and osteochondral defects (where there is damage 
to the articular cartilage and underlying bone) [7, 8]. The procedure involves 
taking a core of the injured cartilage and underlying bone from the patient 
and replacing it with a size-matched transplant of mature hyaline cartilage 
and subchondral bone from a cadaver donor [9, 10]. The theory behind this 
procedure is that the living cartilage cells (chondrocytes) supplied by the 
donor transplant support the production of the cartilage matrix indefinitely 
[11]. Images of an OCA procedure are presented in Figure 3-1. 
 
Figure 3-1: Intraoperative image of an osteochondral allograft transplant procedure in the knee, showing  
(a) marginal excision and preparation of medial femoral condyle, (b) osteochondral allograft preparation, 
and (c) implantation. Source: Fitzgerald et al. 2014 [12] 
In theory osteochondral allograft transplantation can be used to treat chon-
dral and osteochondral defects of all sizes, locations and contours; however, 
it is generally indicated for treatment of lesions greater than 2 cm2. It has 
been mainly used to treat the knee joint but has also been used to treat the 
talus of the ankle, shoulder and elbow [8]. 
Comparators 
There are a range of comparator surgical techniques for treatment of osteo-
chondral defects including osteochondral autologous transplantation, micro-
fracture, drilling, mosaicplasty, autologous chondrocyte implantation (ACI) 
and matrix-induced autologous chondrocyte implantation (MACI). The choice 
of procedure depends on the size and location of the defect [13]. 
 
 
frische oder  
verzögert-frische 
osteochondrale Allograft 
Transplantation (OCA) 
dient der Reparatur 
(osteo)chondraler 
Defekte mithilfe eines 
Knorpel-Knochen-
Transplantats einer 
Leichnamsspende 
für Defekte >2cm2,  
v. a. im Knie-, Sprung-, 
Schulter- & 
Ellbogengelenk 
zahlreiche chirurgische 
Vergleichsverfahren, 
abhängig von 
Defektgröße & 
Lokalisation ... 
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Microfracture and drilling involve the creation of small holes into the sub-
chondral bone to create tunnels to the underlying bone marrow. The bleed-
ing caused by this process results in stem cells flowing into the bone and 
coating the area where the cartilage has been lost. Over time these stem cells 
develop into a new form of cartilage (fibrocartilage) [14-16]. Images of a mi-
crofracture procedure are presented in Figure 3-2. 
 
 
 
Figure 3-2: 
Arthroscopic image of a chondral  
lesion treated with microfracture.  
Source: Mestrimer et al. 2018 [17] 
Osteochondral autograft transplantation is used to address small chondral de-
fects which have deep subchondral damage that is untreatable by microfrac-
ture or drilling [15]. It is a similar procedure to OCA except it involves the 
use of viable hyaline cartilage grafts obtained from the patient rather than 
from a cadaveric donor. As in osteochondral allograft transplantation the graft 
is a core of cartilage and subchondral bone [15, 18].  
Mosaicplasty is a form of osteochondral autograft transplantation where more 
than one graft core is used to treat a single cartilage defect. The cores are im-
planted in a mosaic-like pattern [19]. A visual representation of mosaicplasty 
is present in Figure 3-3. 
 
Figure 3-3: Images of a mosaicplasty procedure showing (a) arthroscopic measurement 
of defect size, (b) open procedure, (c) harvesting of autologous osteochondral 
plugs from lateral supracondylar ridge, (d) insertion of plug through drill 
guide, (e) harvested osteochondral plugs, and (f) cartilage defect 
reconstructed with plugs. Source: Seo et al. 2011 [20] 
... Mikrofrakturierung 
... osteochondrale 
Autograft 
Transplantation 
... Mosaikplastik 
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Autologous chondrocyte implantation can treat larger cartilage defects com-
pared to microfracture or mosaicplasty; however, it involves a two-staged pro-
cedure [18]. The first procedure involves the harvesting of pieces of the pa-
tient’s own cartilage and expanding the chondrocytes in a laboratory. In the 
second procedure the damaged area of cartilage is debrided and the cultured 
chondrocytes injected into the articular defect [15, 18]. Matrix-induced auto-
logous chondrocyte implantation is an extension of autologous chondrocyte 
implantation whereby the expanded autologous chondrocytes are implanted 
on a three-dimensional scaffold which is then inserted into the articular de-
fect [18]. 
A0020 – For which indications has osteochondral allograft 
transplantation received marketing authorisation or CE marking? 
Osteochondral allografts are not classified as medical devices, and therefore 
are not subject to CE marking. 
Human tissue donation is regulated in the European Union under the Euro-
pean Union Tissue and Cells Directives (EUTCD) 2004/23/EC. The EUTCD 
outlines the legal framework for the supply of tissues and cells within the EU, 
to ensure that biological samples meet acceptable safety and quality standards 
[21]. In this regard, individual suppliers of tissue samples that are licensed 
to distribute tissue samples under the EUTCD can distribute within the Eu-
ropean Union. 
Additionally, in Austria tissue donation is regulated under the tissue safety 
law („Bundesgesetz über die Festlegung von Qualitäts- und Sicherheitsstan-
dards für die Gewinnung, Verarbeitung, Lagerung und Verteilung von 
menschlichen Zellen und Geweben zur Verwendung beim Menschen – Ge-
webesicherheitsgesetz“) [22]. Moreover, the principles of tissue and organ do-
nation in Austria is positioned in the „Bundesgesetz über die Transplantati-
on von menschlichen Organen“ (Organtransplantationsgesetz – OTPG) [23].  
B0002 – What is the claimed benefit of osteochondral  
allograft transplantation in relation to other surgical procedures? 
Compared with other methods of repair, such as drilling, microfracture and 
osteochondral autograft transplantation, osteochondral allograft transplanta-
tion can repair almost any size osteochondral defect [11]. An additional ad-
vantage over drilling and microfracture is that osteochondral allograft trans-
plantation restores the lesion using mature joint cartilage rather than fibro-
cartilage which has poor biomechanical properties and is less durable [19]. 
Compared with osteochondral autograft transplantation and mosaicplasty, 
where grafts are obtained from the patient rather than a donor, there is no 
graft site related morbidity with osteochondral allograft transplantation [24]. 
The advantage of osteochondral allograft transplantation compared with ACI 
and MACI is that it is a single-stage procedure whereas ACI and MACI are 
two staged-procedures. It can require two to three weeks between the first 
and second stage to culture the chondrocytes and the second stage requires 
an arthrotomy [24]. 
... (Matrix-assistierte) 
autologe Chondrozyten 
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B0003 – What is the phase of development and implementation of 
osteochondral allograft transplantation and other surgical procedures? 
The use of osteochondral allograft transplantation and its comparator pro-
cedures for the repair of articular cartilage defects have all been extensively 
evaluated in clinical studies ranging in level of evidence [25]. 
Microfracture is reported to be the oldest, most inexpensive and commonly 
used method for treating osteochondral defects whilst osteochondral autograft 
transplantation is one of the oldest cartilage transplant procedures for osteo-
chondral defects [15]. 
The use of osteochondral allograft transplantation around the world varies 
owing to the different regulatory and logistical issues in each country, as well 
as the cost of obtaining and processing allografts [26]. Canada and the USA 
have established programs for fresh osteochondral allografts [27].  
Autologous chondrocyte transplantation for articular cartilage repair devel-
oped after osteochondral allograft transplantation. A paper on regulatory ap-
proval for autologous human cells and tissue products in the USA, the Eu-
ropean Union and Japan noted that as of October 2013 four products derived 
from autologous chondrocytes for the repair of cartilaginous defects of the 
femoral condyle were approved by the European Medicines Agency [28]. 
 
Administration, Investments, personnel and tools  
required to use the technology and the comparator(s) 
B0004 – Who administers osteochondral allograft transplantation  
and other surgical procedures and in what context and level of care  
are they provided? 
B0008 – What kind of special premises are needed to use  
osteochondral allograft transplantation and other surgical procedures? 
Osteochondral allograft transplantation and its comparator procedures should 
only be performed by orthopaedic surgeons experienced in cartilage surgery 
and with specific training in these procedures.  
According to the submitting hospitals, osteochondral allograft transplanta-
tion and its comparator procedures should be performed in university hospi-
tals/departments for orthopaedics, by orthopaedic surgical specialists and 
qualified surgical staff. Further, a sterile operation theatre with an anaesthet-
ic workplace is required. 
B0009 – What supplies are needed to use osteochondral  
allograft transplantation and other surgical procedures? 
Preoperative imaging using radiographs or magnetic resonance imaging is 
required prior to osteochondral allograft transplantation to calculate the ap-
propriate allograft size [29, 30]. 
The surgical supplies needed depends on the surface to be grafted and the 
surgical technique performed (shell or dowel). Dowel allografts involve cy-
lindrically coring out the defect and inserting a matched cylindrical dowel in 
to the recipient site. If the size of location of the lesion does not permit the 
use of the dowel technique than the shell graft technique is used. This in-
volves matching donor tissue to the recipient defect using a free-hand ap-
proach. The size of the defect is estimated using cannulated, cylindrical siz-
ing guides [8, 31]. 
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älteste & kosten-
günstigste Methode  
zur Behandlung 
osteochondraler Defekte 
 
 
osteochondrale 
Autograft 
Transplantation ist 
ältestes Verfahren zur 
Knorpeltransplantation 
Anwendung 
osteochondraler 
Allograft 
Transplantationen 
variabel, da 
unterschiedliche 
Regularien in Ländern 
von orthopädisch 
chirurgischen 
SpezialistInnen & 
qualifiziertem Personal 
durchzuführen 
Universitätskliniken, 
Abteilung für 
Orthopädie,  
steriler OP erforderlich 
präoperative  
Bildgebung erforderlich 
benötigte chirurgische 
Hilfsmittel abhängig von 
zu transplantierenden 
Oberfläche & 
verwendeten 
Operationstechnik 
Description and technical characteristics of technology 
LBI-HTA | 2019 25 
Equipment required for the dowel technique includes cutting guides, guide-
wire reamers, a padded tamp and cutting guides. Also required is a pressur-
ised pulsed solution to remove residual bone marrow. Additional equipment 
is required for the shell graft technique including calipers, reamers, depth-
gauge, high-speed burr, reciprocating and oscillating saws, bone files and/or 
rasp owing to the need for measured resection and sculpting of the bone and 
cartilage [31]. 
Both techniques require scalpels, prophylactic antibiotics and anaesthesia 
[30]. Most graft can be fixed in place using pressure applied by the surgeon; 
however, other options should be available including bioabsorbable pins and/ 
or low-profile interfragmentary screws (≤ 3mm in diameter) [31]. A tourni-
quet and leg holder may be used in procedures involving the knee [32]. 
Fresh grafts must be stored at 4°C. Storage solutions include saline solution, 
Ringer’s lactate or a serum-free media consisting of glucose, salts, amino ac-
ids and fetal bovine serum. It is recommended that fresh grafts be used with-
in 28 days of harvesting. Fresh-frozen grafts are stored at -80°C [8,30].  
 
Regulatory & reimbursement status  
A0021 – What is the reimbursement status of osteochondral  
allograft transplantation? 
Currently, OCA for osteochondral defects are not included in the Austrian 
DRG-system (Leistungsorientierte Krankenanstaltenfinanzierung/LKF). There-
fore, the intervention itself is not reimbursed by the Austrian health care sys-
tem. However, the intervention could be billed with another code, e.g. for ar-
throscopic operations of the knee or ankle joint (Code NF020 – Arthrosko-
pische Operation des Kniegelenks; NG020 – Arthroskopische Operation des 
Sprunggelenks). 
 
Skalpelle, 
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Anästhesie erforderlich 
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der Intervention in 
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4 Health problem and current use 
Overview of the disease or health condition 
A0001 – For which health conditions, and for what purposes  
is osteochondral allograft transplantation used? 
Fresh or delayed-fresh osteochondral allograft transplantation has been used 
to treat chondral and osteochondral lesions in the knee, talus of the ankle, 
shoulder and elbow [32]. 
According to the International Cartilage Regeneration and Joint Preservation 
Society “The most common reasons for performing osteochondral allograft 
transplantation are: 
 A focal cartilage lesion greater than 2cm2 
 Re-treatment of previous cartilage surgery such as microfracture,  
autologous osteochondral transplantation or autologous chondrocyte 
transplantation 
 Severe (type III or IV) osteochondritis dissecans 
 Osteonecrosis  
 Joint reconstruction after a fracture, known as post-traumatic  
reconstruction [11]” 
Contraindications are: 
 Advanced or diffuse degenerative changes 
 Multicompartmental arthrosis [33] 
Relative contraindications are: 
 Inflammatory arthropathies 
 Uncorrected joint malalignment and/or ligamentous instability 
 Meniscal insufficiency [33] 
In addition to the above contraindications it has been reported that osteo-
chondral allograft transplantation should be avoided in patients who are 
obese, have altered bone metabolism or are affected by tumours [33]. 
A0002 – What is the disease or health condition  
in the scope of this assessment?  
The health condition under investigation for this assessment is osteochondral 
defects. An osteochondral defect is an area of damage to the joints involving 
the articular cartilage and adjacent subchondral bone [34]. 
Articular cartilage defects are graded using the International Cartilage Regen-
eration and Joint Preservation Society and Outerbridge’s classifications [35]. 
Table 4-1: Classification of cartilage defects by Outerbridge [36] 
Grade Characteristics 
0 Normal 
1 Softening and swelling of cartilage 
2 Fragmentation and fissuring, less than 0.5 inches in diameter 
3 Fragmentation and fissuring, greater than 0.5 inches in diameter 
4 Erosion of cartilage down to exposed subchondral bone 
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Table 4-2: Classification of chondral defects by International Cartilage  
Repair Society [35] 
Grade Characteristics 
0 Normal 
1 Nearly normal (soft indentation and/or superficial fissures and cracks) 
2 Abnormal (lesions extending down to <50% of cartilage depth) 
3 Severely abnormal (cartilage defects >50% of cartilage depth) 
4 Severely abnormal (through the subchondral bone) 
 
A0003 – What are the known risk factors for osteochondral defects? 
Osteochondral defects can be caused by a range of factors. Individuals who 
play sports where traumatic injuries can occur are at risk of acquiring oste-
ochondral defects. Repetitive trauma, a genetic predisposition and abnormal 
bone development are also associated with the development of osteochondral 
lesions [37, 38]. 
A0004 – What is the natural course of osteochondral defects? 
Osteochondral lesions have limited ability to self-repair because cartilaginous 
tissue has no direct blood supply. The lesions may heal by forming fibrous 
or fibrocartilaginous tissue but this is not as durable as the hyaline cartilage 
it replaces and eventually fails [35]. Without treatment lesions may get larg-
er and harder to treat over time. Conservative treatments such as non-stero-
idal anti-inflammatory drugs only delay the progress. If left untreated, articu-
lar damage strongly predisposes patients to early joint degeneration and os-
teoarthritis [13, 39, 40]. 
 
Effects of the disease or health condition on the individual  
and society 
A0005 – What is the burden of disease for patients  
with osteochondral defects? 
Articular cartilage lines the end of the bones is responsible for cushioning of 
the joints and smooth gliding of bones during movement. The loss in carti-
lage associated with osteochondral lesions means that the joints are no longer 
cushioned and can rub each other causing pain and inflammation during ac-
tivities that put pressure on the joint [13, 39]. Other symptoms can include 
catching, locking and instability [41]. These symptoms have a negative effect 
on quality of life and a person’s ability to perform daily activities. For very ac-
tive people, such as professional or amateur athletes or people with jobs in-
volving manual labour, the physical impairment created by an osteochondral 
lesion has a major impact on their lives including the potential loss of em-
ployment [7,42].  
A0006 – What are the societal consequences of osteochondral defects? 
Osteochondral defects can result in ongoing costs for physiotherapy and med-
ication. Left untreated, people with osteochondral defects are predisposed to 
developing osteoarthritis which may require joint replacement. Indirect costs 
associated with osteochondral defects include loss in time and productivity. 
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In Austria, 78,277 surgeries of the knee joint and 2,855 surgeries of the ankle 
joint were performed in 2016 [43]. Out of the surgeries of the knee joint, a 
total of 37,364 interventions were arthroscopic surgeries [44]. 
However, neither information on the number of OCA interventions of the 
knee or ankle joint performed, nor information regarding the prevalence or 
incidence of osteochondral defects have been identified. 
 
Current clinical management of the disease or health condition 
A0024 – How are osteochondral defects currently diagnosed according  
to published guidelines and in practice? 
We could not identify published guidelines on the diagnosis of osteochondral 
defects. A consensus statement on surgical management of symptomatic ar-
ticular cartilage defects of the knee from the United Kingdom stated, “History 
and physical examination alone are not diagnostic, and patients usually undergo 
plain radiography of the knee to evaluate alignment of the joint, to detect the pres-
ence of any radio-opaque loose bodies and determine signs of arthritis” [41]. They 
further state that “Magnetic resonance imaging (with or without gadolinium 
enhancement) can identify and partly quantify articular cartilage defects.” 
For assessment of lesion size and functional integrity of the surrounding tis-
sue they state that arthroscopy is the gold standard. A practice guideline on 
management of articular cartilage defects of the knee stated in the introduc-
tion that the gold standard for diagnosis of chondral injuries is magnetic re-
sonance imaging [35]. 
A0025 – How are osteochondral defects currently managed  
according to published guidelines and in practice? 
No evidence-based guidelines for the treatment of osteochondral defects were 
identified in this review. 
A technology appraisal on autologous chondrocyte implantation for treating 
symptomatic articular cartilage defects of the knee by the National Institute 
for Health and Care Excellence (NICE) states that people with articular car-
tilage defects will first be offered best supportive care. This includes physio-
therapy, analgesia, corticosteroid injections and hot or cold application to the 
joint. Exercise and weight loss is also encouraged. Surgery is only considered 
in people whose symptoms persist despite best supportive care [42]. 
The NICE guidance on mosaicplasty for symptomatic articular cartilage de-
fects of the knee reported that there is no uniform approach to their man-
agement. Treatment choice (such as osteochondral allograft transplantation 
and comparator techniques listed in B0001) depends on the size of the defect 
and its location [45].  
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Target population 
A0007 – What is the target population in this assessment? 
The target population includes patients with osteochondral defects (of any 
joint) who have failed conservative management or primary surgery. 
A0023 – How many people belong to the target population?  
No information on the incidence or prevalence of osteochondral defects in 
the knee, ankle or shoulder of Austrian or European populations was identi-
fied. Moreover, the true incidence is unknown, because not all osteochondral 
defects cause symptoms. 
Studies on large datasets of patients who have undergone knee arthroscopies 
have estimated the number of patients who might be suitable for cartilage 
repair procedures using localised full thickness lesions (ICRS grade 3 and 4) 
as selection criteria. Figures range from 5.3% to 7.0% of all knee arthrosco-
pies when restricted to patients under 40 years of age [46, 47], and 9.0% to 
11.0% of all knee arthroscopies in studies that have included all analysed pa-
tients regardless of age [47, 48]. 
A0011 – How much is osteochondral allograft transplantation utilised? 
No data could be identified to estimate the overall size of the population eli-
gible for osteochondral allograft transplantation. Based on the information 
provided by the submitting hospitals, the estimated annual utilisation of 
OCA in the submitting hospitals is around 2-5 procedures. In contrast, the 
annual utilisation in Austria is estimated to be around 40 procedures, of which 
20 are fresh and 20 are delayed-fresh OCA. 
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5 Clinical effectiveness 
5.1 Outcomes 
The following outcomes were defined as crucial for the recommendation: 
 Decrease in pain 
 Increase in functionality  
 Necessity of total joint replacement 
 Increase in quality of life 
Symptoms associated with osteochondral defects of the knee and ankle in-
clude pain, swelling, catching and locking of the joint [41, 49]. These may 
impair function, limit a patient’s ability to perform their usual activities and 
have a negative impact upon quality of life. Approaches taken for the man-
agement of such defects seek to relieve pain, improving functionality and en-
couraging the repair of damaged tissue [49, 50]. 
Decrease in pain was selected as a crucial outcome. Pain is a key symptom 
associated with osteochondral defects; with relief of pain being a common 
management objective. Various questionnaires are available which elicit an 
indication of the level of pain experienced by a patient. These may be gener-
ic or disease specific.  
Both the Western Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC) and the Knee Injury and Osteoarthritis Outcome Score (KOOS) 
include pain subscales which measure disease-specific knee pain [51]. A vis-
ual analogue scale (VAS) is a generic tool that is often used to elicit a meas-
ure of pain. Minimum clinically important differences (MCID) for WOMAC 
(pain subscale) have been reported ranging from 22.9 to 36 at two years fol-
lowing knee surgery [52], whereas a change of 19.9 for VAS is clinically rele-
vant for patients with knee pain [53]. MCIDs for KOOS pain subscales have 
not been calculated in any patient population [52].  
Increase in functionality was selected as a crucial outcome. Examples of tools 
that measure functionality and which may be relevant to knee or ankle pop-
ulations are listed below: 
 The KOOS is a patient-completed questionnaire; eliciting a patient’s 
perception of their knee/knee-problems (specifically, in cases of post-
traumatic osteoarthritis or injuries that may lead to posttraumatic os-
teoarthritis) [51]. It contains 5 domains – pain, symptoms, activities 
of daily living (ADL), sports and recreational activities, and knee re-
lated QoL. The MCID for KOOS physical function scores are 2.2, with 
a change of 15 representing moderate improvement in patients with 
knee pain [54]. 
 The WOMAC is a self-administered or interview-administered ques-
tionnaire designed to assess the course of disease or response to treat-
ment in patients with knee or hip osteoarthritis [51]. It contains 3 sub-
scales – pain, stiffness and function. The MCID for WOMAC has not 
been calculated for cartilage repair procedures; MCIDs range from 19-
33 points at two years following knee replacement [52]. 
 The International Knee Documentation Committee (IKDC) questi-
onnaire can be used in patients with a variety of knee conditions to 
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measure changes in symptoms, function and sports activities due to 
knee impairment [51]. The MCID for IKDC scores is 6.3 at 6 months, 
and 16.7 at 12 months following cartilage repair [52]. 
 The Foot and Ankle Abilities Measure (FAAM) is a self-reported tool 
which assesses the physical function of patients with musculoskeletal 
disorders of the leg, foot or ankle [55]. The MCID for FAAM scores 
ranges from 9 to 77 points (median 32.5 )[56]. 
Necessity of total joint replacement was selected as a crucial outcome. Pa-
tients who have suffered an osteochondral defect are at a heightened risk of 
future osteoarthritis [50]. 
To comprehensively evaluate the ability of OCA to prevent or delay the need 
for total joint replacement, long-term follow up data is essential. 
Quality of life (QoL) was selected as a crucial outcome. Reducing symptoms 
and improving functionality may improve a patient’s quality of life, with im-
proved QoL considered the ‘final’ outcome. Disease specific or generic ap-
proaches may be taken to measure QoL. For example, the KOOS, which was 
introduced above, is a knee-specific measurement tool that contains a QoL 
subscale [51]. The MCID for KOOS-QoL is change of 8 points in patients with 
osteoarthritis [54]. The SF-36 is a widely used, non-disease specific measure 
of QoL. The MCID for SF-36 scores ranges from 7.8 to 17 in patients with 
knee osteoarthritis [53]. 
Furthermore, the following outcome was considered important, but not crucial 
to the decision:  
 Return to daily/sports/physical activities 
The success of treatment in increasing functionality is directly linked to a pa-
tient’s ability to perform activities of daily living, sports and physical activi-
ties. Given this dependence, return to activities of daily living was considered 
important, though not crucial to the decision-making process. 
 
 
5.2 Included studies 
Studies evaluating the effect of fresh or delayed-fresh osteochondral allograft 
transplantation (OCA) for osteochondral defects were considered; however, 
relevant studies were only identified on patients with defects in the ankle or 
knee. 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table A-6. 
Ankle 
Only the RCT comparing OCA to another surgical procedure for osteochon-
dral lesions of the ankle was identified. Evidence from this randomised trial 
was considered when evaluating the effectiveness of OCA to treat osteochon-
dral defects in the ankle. 
The RCT, conducted in the USA, enrolled 40 patients with osteochondral le-
sions of the talar dome (OLT) [57]. Patients were randomised to receive ei-
ther an OCA or osteochondral autograft transplantation. These lesions were 
either recurrent in nature (i.e. had failed initial arthroscopic treatment) or 
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were of a size 1.5cm2 or greater. In both treatment arms, 75% of patients had 
recurrent OLTs whilst the remaining 25% had large OLTs with no prior sur-
geries. 
The average age and gender distribution of patients in the allograft and auto-
graft groups were similar (40 vs 41 years, 63% vs. 55% male, respectively); as 
was mean chondral lesion size (1.8cm2 vs. 1.6cm2) [57]. Mean follow up times 
for the intervention and comparator groups were 3.4 and 2.9 years, respec-
tively. Post-operative outcome measures presented are those taken at final 
follow up.  
Amongst those receiving an allograft, 87.5% vs. 80% of OLTs were anterior 
or central, whilst 12.5% vs. 20% were posteromedial [57]. 
Patients were eligible so long as their lesion did not involve the medial or 
lateral shoulder of the talar dome [57]. Four patients in the allograft group 
were excluded due to significant involvement of the medial or lateral shoul-
der of the talar dome found intraoperatively. Only the 16 patients who re-
ceived the appropriate intervention were considered in all analyses. Twenty 
patients remained in the autograft group for analysis.  
Concurrent procedures were not reported. It is possible none occurred how-
ever, this was not specified.  
Knee 
For the indication ‘osteochondral defect in the knee’ no randomised or com-
parative trials were retrieved thus, we considered prospective case-series with 
at least 15 patients and at least 24 months follow up when evaluating the ef-
fectiveness of OCA to treat osteochondral defects in the knee. 
Four single arm, prospective case series were considered; two were conduct-
ed in the USA and two in Canada [58-61]. Patient numbers ranged from 17 
to 91. 
Two studies had 2-year follow-ups, from which two-year, post-operative out-
comes measure data could be extracted [58, 59]. Follow-up in the remaining 
two studies ranged from 1.9 to 4 years, and from 0.3 to 14.5 years. Post-oper-
ative outcome data from ‘final follow up’ could be extracted from one of these 
studies [60]. Relevant outcomes presented by the final study were sparse and 
did not involve a pre- vs. post-operative comparison [61]. 
Prior surgeries were reported in three of the four studies [58-60]. Where re-
ported, mean number of prior surgeries per patients varied from 0.7 to 1.7.  
Only two studies reported concurrent procedures [58, 60]. These included, 
non-exhaustively, tibial osteotomy, meniscal transplant, ACL reconstruction 
and Herbert screw removal.  
Two studies specified the transplant location, which included the lateral tib-
ial plateau, lateral femoral condyle and medial femoral condyle [59, 60]. One 
study specified a femoral condyle location but location on the condyle was 
not further specified [58]. The final study provided no information of trans-
plant location [61]. 
Only one study specified the grade of cartilage defect required to be eligible 
for an OCA. Specifically, this was a grade 4 International Cartilage Repair 
Society (ICRS) articular cartilage defect [58]. Other studies did not report 
the grade of cartilage defect. 
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5.3 Results 
Mortality 
D0001 – What is the expected beneficial effect  
of osteochondral allograft transplantation on mortality? 
D0003 – What is the effect of osteochondral allograft transplantation  
on the mortality due to causes other than osteochondral defects of the 
knee or ankle? 
Osteochondral defects are not considered life threatening and OCA is not in-
tended to affect patient survival or life expectancy. These research questions 
are not relevant. Procedure-related mortality was considered as a safety-out-
come only. 
 
Morbidity 
D0005 – How does osteochondral allograft transplantation affect 
symptoms and findings (severity, frequency) of osteochondral defects? 
The critical outcome ‘pain’ was considered when answering this research 
question. 
Ankle 
A 10-point VAS was used to assess pre- and post-operative pain [57]. The 
study did not report mean changes in pain score over time. Post-operative 
pain was compared between the allograft and autograft groups. The differ-
ence was not significant (2.7 vs. 2.2, p=0.15). Mean pre-operative pain was 
7.8 (range 5-10) and 7.9 (range 4-10) for the allograft and autograft groups, 
respectively. Pre-operative scores were not compared statistically. 
Knee 
Patient-reported pain in the case series was elicited using knee-specific 
tools. Pain was directly measured through use of the pain-specific subscales 
of the KOOS and WOMAC questionnaires. 
Two studies measured pain via the KOOS-pain domain pre-operatively and 
two years post-operatively [58, 59]. Both studies found a statistically signifi-
cant difference between pain pre- and post-operatively (52.5 vs. 79.0, p<0.001 
and 59 vs. 74, p=0.028). 
One of these studies also administered the WOMAC questionnaire to patients 
[59]. The significant improvement in pain observed when using the KOOS 
was supported by the findings of the WOMAC questionnaire (WOMAC pain 
subscale score: 91.0 vs. 96.1, p=0.002); however, this difference was not clin-
ically important [52]. 
The PICO considered pain and functionality as the most relevant outcomes 
to express symptoms, specifying these as outcomes of interest. However, more 
general measures of patient-reported symptoms are available (measured on 
the symptom domains of the KOOS and the Modified Cincinnati Knee-Rating 
System tools). Whilst not directly relevant to the pre-defined outcomes, the 
results are discussed below for comparative purposes. 
Amongst the two studies that reported overall KOOS scores, there was varia-
tion in the significant/non-significant findings pertaining to improvement in 
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symptoms post-operatively (p=0.01 and p=0.172) [58, 59]. A third study 
which administered a modified Cincinnati Knee-Rating System found a sig-
nificant difference in symptoms between pre- and post-operative time points 
(21.9 vs 32.5, p<0.03) [60], it is unclear whether this difference is clinically 
meaningful. 
D0006 – How does osteochondral allograft transplantation affect 
progression (or recurrence) of ostechondral defects? 
‘Necessity of total joint replacement’ was the outcome used to inform this 
research question. Other measures that may be considered relevant include 
revision, reoperation, and graft failure; these are reported in response to Ques-
tion C0008. No studies specified this as an outcome measure of interest. 
Ankle 
No comparative data was available on this outcome measure. Two patients in 
each group required a revision surgery (this involved conversion to alternate 
therapy), although these were due to graft non-unions rather than progression 
or recurrence of the disease [57]. 
Knee 
All studies discussed additional procedures required post OCA. In two of the 
studies, it was reported that at least one patient underwent a subsequent to-
tal knee arthroplasty [58, 61]. Across the two studies, a total of 7 of 125 (5.6%, 
range 3% to 6.6%) patients progressed to a total knee replacement at two years 
follow-up. 
Reliable, long-term follow up data is required if this research question is to 
be answered robustly. 
 
Function 
D0011 – What is the effect of osteochondral allograft transplantation  
on patients’ body functions? 
This question is answered in the subsequent section (D0016 – How does the 
use of osteochondral allograft transplantation affect activities of daily living?) 
D0016 – How does the use of osteochondral allograft transplantation 
affect activities of daily living? 
The critical outcome ‘functionality’ was considered when answering this re-
search question. 
Ankle 
Comparative data measured using the Foot and Ankle Ability Measure (FAAM) 
questionnaire informed the answer to this research question. 
Pre- and post-operative FAAM scores of each treatment arm were reported 
however, mean changes in FAAM scores between these time points were not 
[57]. 
The difference in postoperative FAAM score between the two groups was 
found not to be statistically significant (80.7 vs. 85.5, p=0.25). 
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Knee 
The KOOS, WOMAC, IKDC and Modified Cincinnati knee rating system 
tools were used interchangeably by three of the four included case series to 
assess knee function [58-60]. Where possible, function-specific domains have 
been reported. These include: 
 Function subscales of the WOMAC and Modified Cincinnati knee 
rating system tools 
 Activities of daily living (ADL) and sports and recreation domains  
of the KOOS tool. 
The IKDC is made up of three domains – symptoms, sports and daily activi-
ties and knee function however, only an aggregate score is reported. 
KOOS – ADL and sports and recreation domains 
Two studies used the KOOS tool [58, 59]. Both studies reported significant 
differences between pre- and two-year post-operative measures on the sports 
and recreation domain (21.2 vs. 54.4, p=0.002 and 37 vs. 57, p=0.005). There 
was however discrepancy in significant/non-significant findings on the ADL 
domain (68.5 vs. 84.8, p=0.004 and 69 v 83, p=0.058). 
WOMAC – function 
Only one study used the WOMAC questionnaire. A statistically significant 
change in functionality pre- vs. two years post-operatively, as measured on 
the function domain, was observed (68.1 vs. 83.1, p=0.03) [59]; however, this 
difference did not fall within the range of MCIDs [52]. 
IKDC 
Two studies used the IKDC questionnaire. Both reported significant changes 
between baseline and follow-up scores; however, these were below the MCID 
for a minimum 12 months follow-up after cartilage repair [52]. For Brown et 
al. (2011), this was between pre-operative and two years post-operative time 
points, (45 vs. 62, p<0.001) [58]. For LaPrade et al. (2009), this was between 
pre-operative scores and scores taken at last follow-up, the timing of which 
is uncertain (52 vs. 68.5, p<0.03) [60]. 
Modified Cincinnati knee rating system – function  
In addition to the IKDC, LaPrade et al (2009) administered the Modified Cin-
cinnati Knee Rating System [60]. Similar to their findings on the IKDC, sig-
nificant functionally differences between baseline and follow-up were report-
ed on the function domain (27.3 vs. 36.5, p<0.01). 
Based on the findings of the three prospective case series that provided func-
tionality outcome measures, it would appear OCA leads to significant im-
provements in functionality. Nonetheless, these results should be interpret-
ed with caution given the relatively small sample sizes (n=17 up to n=34) 
and single-centre designs of all studies.  
Moreover, it is impossible to conclude whether any functional improvement 
is significantly different from that which would occur when the next best al-
ternative is employed. 
 
3 Studien verwendeten 
4 verschiedene Skalen 
2 Studien: s.s. 
Unterschiede prä- & 
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2 Studien: s.s. 
Verbesserung prä- vs. 
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Follow-Up der Pat.) 
1 Studie: s.s. 
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prä- vs. postoperativ 
Verbesserung 
Funktionalität in 
Studien, ABER kleine 
Stichproben und  
nicht-kontrolliertes 
Studiendesign 
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Health-related quality of life 
D0012 – What is the effect of osteochondral allograft transplantation  
on generic health-related quality of life? 
No generic health related quality of life information was extracted from the 
included studies. 
One study did report SF-36 scores; however, only combined scores for knee 
and shoulder patients were provided. It was not possible to disaggregate the 
results, therefore; this data was not extracted. 
D0013 – What is the effect of osteochondral allograft transplantation  
on disease-specific quality of life? 
Ankle 
No comparative data was identified to answer this question for this indication. 
Knee 
The quality of life subscale of the KOOS questionnaire measures disease-
specific quality of life.  
Disease specific quality of life was measured preoperatively and 2 years post-
operatively in two studies. Both studies reported a significant improvement 
in health-related quality of life (p<0.001 and p=0.001) [58, 59]. Neither study 
reported a mean difference; only pre- and post-operative scores, and a p-value.  
 
Patient satisfaction 
D0017 – Was the use of osteochondral allograft transplantation 
worthwhile? 
No data was identified to answer this question for either indication.  
 
 
keine Evidenz 
keine Evidenz  
zum Sprunggelenk 
2 Studien: s.s. 
Verbesserung der 
Lebensqualität prä- vs. 
postoperativ (2 Jahre) 
keine Evidenz 
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6 Safety 
6.1 Outcomes 
The following outcomes were defined as crucial to derive a recommendation: 
 Procedure-related mortality 
 Adverse events (peri- and post-operatively) 
 Transplant failure rates 
Procedure-related mortality is considered to be a crucial safety concern. Any 
death that occurred during or within 30 days of the procedure, or that could 
be related directly to OCA implantation, revision or removal were relevant 
to this outcome. Examples of procedure-related mortality may include infec-
tion. 
Adverse events specifically related to the intervention (or comparator) were 
considered a crucial safety concern. These may include, for example, disease 
transmission or an immune response (OCA), and donor site morbidity (auto-
graft)[62]. 
Transplant failure rate was considered a crucial safety outcome. Failure of an 
allograft may be defined in a number of ways, including ongoing pain and de-
bilitation, failure of graft incorporation or necessity of an alternate surgery 
following transplantation. 
Furthermore, additional outcome measures were considered important to  
inform the decision, although not crucial:  
 Re-admission 
 Re-operation/additional surgery 
Re-operations/additional surgery and re-admissions associated with the inter-
vention (or comparator) are most likely necessary in the case of an adverse 
event or a graft failure. Given adverse events and transplant failure rates were 
defined as crucial outcomes, re-operations and re-admissions were considered 
important, but no crucial to inform a recommendation. 
 
 
6.2 Included studies 
Study characteristics and results of included studies are displayed in Table 
A-1 and Table A-2 and in the evidence profile in Table A-6. 
Ankle 
In addition to the RCT, one prospective case series was included in safety 
analysis for ankle OCA [57, 63]. Follow-up time in the randomised trial 
ranged from 1 to 6.4 years (mean follow up times for the allograft and auto-
graft groups were 3.4 and 2.9 years, respectively). In the case-series, follow-
up time ranged from 2 to 7 years, with mean follow-up of 4.1 years.  
The randomised trial has been discussed in detail above (Section 5.2).  
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The case-series included 16 patients and a total of 17 ankles undergoing fresh 
allograft transplantation for a talar lesion [63]. Mean patient age was 35.8 
years and 50% were male. Sixteen of the 17 ankles had single or multiple sur-
geries prior to the allograft transplant. The most common transplant location 
was the posteromedial talar (64.7%). Transplants also occurred in the medial 
talar (17.6%), posterolateral talar (11.85) and the anterolateral talar (5.9%). 
All patients had a least 2 years of follow up data. 
The severity/grade of the osteochondral lesion was not reported; however, all 
except one lesion had at least one dimension greater than 15mm [63]. 
Concurrent procedures were not reported. It is possible none occurred; how-
ever, this was not specified. 
Knee 
Four case-series informed the safety evaluation of OCA for osteochondral le-
sions of the knee [58-61].These studies have been discussed in detail above 
(Section 5.2).  
 
 
6.3 Results 
Patient safety 
C0008 – How safe is osteochondral allograft transplantation in 
comparison to other surgical interventions? 
The outcomes ‘procedure-related mortality’, ‘adverse events’ and ‘transplant 
failure rates’ were considered when answering this research question.  
None of the included studies, for ankle or knee, reported any cases of proce-
dure-related mortality.  
Allograft vs. Autograft (ankle) 
Only one study provided comparative safety data. This pertained to the use 
of osteochondral allograft vs. osteochondral autograft transplantation for le-
sions of the talar dome. 
The adverse events reported included painful graft non-unions (18.8% vs. 
10.0%), postoperative superficial wound blistering (0.0% vs. 5.0%), anterior 
ankle arthritis (6.3% vs. 0.0%) and postoperative knee complications (0.0% 
vs. 30.0%) [57]. 
Graft failure rates were not reported explicitly; however, four of the five pa-
tients who experienced a graft non-union (12.5% vs. 10.0%) required removal 
of the graft (RR=1.25, 95% CI 0.20 to 7.92). 
Notably, there was a relatively high frequency (30%) of donor site morbidity 
associated with the autograft approach, which is a known disadvantage [62]. 
Single arm (ankle) 
Five (of 17) grafts were considered a failure in the case-series [63]. These 
grafts had either failed to incorporate post-operatively or failed to relieve 
symptoms. Two of these ‘failed’ grafts required a subsequent arthrodesis pro-
cedure. Another two of the ‘failed’ grafts failed to incorporate post-operative-
ly and one patient withdrew with ongoing symptoms. 
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An additional 2 grafts were considered ‘poor’. These patients required sub-
sequent arthroscopic debridement to reduce ongoing symptoms.  
There was one occasion of a malunion of a medial malleolar osteotomy site 
reported however this did not require additional treatment. 
No clear protocol for capturing adverse events was reported in the methods 
section, therefore, it is possible that not all relevant adverse events have been 
reported. 
Single arm (knee) 
Two studies report transplant failure rates of 7% (n=2) and 11.8% (n=2) [58, 
59]. In these studies, ‘failure’ was defined either (1) upon computed tomogra-
phy scan assessing graft incorporation, and (2) as requiring reoperation due 
to ongoing symptoms post-operatively. 
Adverse events included, non-exhaustively, superficial cellulitis, deep vein 
thrombosis and pulmonary embolism, fibrosis impinging adjacent meniscus 
and fragmentation or delamination of the graft. 
Where fragmentation or delamination of the graft was identified, this was up-
on arthroscopic investigation at the time of either (1) a subsequent procedure, 
or (2) upon defining the graft as a failure due to ongoing pain and debilitation 
[58, 59]. 
Only one study specified that patients were monitored for complications [59]. 
Two of the three remaining studies indicated routine follow-up exams, at spec-
ified time points, in their methods sections [58, 60]. Adverse events may have 
been recorded at these exams however, relying on patient reporting of events 
leaves open the possibility that not all adverse events were captured.  
C0002 – Are there harms related to dosage or frequency  
of applying ostechondral allograft transplantations? 
The available data could not sufficiently answer this research question. 
Revision/subsequent operations are reported by all studies however this is 
rarely a revision/repeat of the OCA surgery itself. Only one study mentioned 
the occurrence of a ‘re-transplant’, which occurred in three of 91 patients (3.3%) 
[61].  
It is unclear whether a second OCA would commonly be considered upon fail-
ure of an initial transplant and whether this would incur any additional risks.  
C0004 – How does the frequency or severity of harms change  
over time or in different settings? 
Available data could not sufficiently answer this research question. Whilst 
adverse events and graft failures may be reported, the timing post transplan-
tation when these occurred is not clearly presented. 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of osteochondral allograft transplantation? 
Ankle 
Surgical approach (anterior distal tibial plafondplasty vs. medial malleolar osteotomy) 
Ahmad et al. (2016) compared the post-operative outcome scores of patients 
dependent on the approach that was taken to expose their OLT during surgery 
(anterior or medial ankle exposure) [57]. No significant differences were found. 
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Knee 
Number of grafts required (single vs. multiple) 
It appears that patients with large osteochondral lesions requiring double 
grafts may be at a higher risk of graft failure.  
The two failures reported by Cinats et al. (2018) occurred in patients who re-
ceived a double dowel graft [59]. Likewise, the two failures reported by Brown 
et al. (2011) occurred in patients who had multiple grafts [58]. 
Region of the knee (weightbearing vs. non-weightbearing zones) 
Brown et al. (2011) consider the degree of graft incorporation stratified by re-
gion of transplantation [(A) anterior indirect weightbearing region, (B) direct 
weightbearing region and (C) posterior indirect weightbearing region]. Of 
note, 8 of 11 (72.7%) of grafts performed in the posterior indirect weightbear-
ing region had <50% incorporation [58]. Moreover, the two failures reported 
in this study each partially involved this posterior, non-weightbearing zone. 
Gender and concurrent procedures 
LaPrade et al. (2009) found no statistically significant differences in function-
ality outcomes between male and female patients, nor between patients who 
received a concurrent procedure and those who did not [60]. 
C0007 – Are osteochondral allograft transplantations  
or other surgical approaches associated with user-dependent harms? 
No evidence was identified which could answer this question. 
 
Investments and tools required 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of osteochondral allograft transplantation and  
other surgical approaches? 
Currently there is insufficient evidence to inform the long-term safety of this 
procedure. Randomised controlled trials with at least 2 years of follow-up, 
are necessary to determine the relative effectiveness of OCA compared to 
other surgical procedures. Long-term follow-up studies with outcomes meas-
ured at standardised follow-up intervals are necessary to determine long-term 
failure rates and re-operation rates. 
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7 Quality of evidence 
Risk of bias in the included randomised controlled trial was appraised using 
the Cochrane RoB tool Version 2.0 [5], and is presented in Table A-3 in the 
Appendix. The study had a high risk of bias, attributable to inadequate ran-
domisation, allocation concealment, and blinding of both the patients and 
investigators.  
Risk of bias in the single arm studies was appraised using the IHE appraisal 
tool for case series studies [64]. The appraisal is presented in Table A-4 of 
the Appendix. 
The included studies varied in the level of bias attributable to them. Most 
studies had a moderate risk of bias, one suffered from serious risk of bias and 
one had a relatively low risk of bias. The main contributors which increased 
the risk of bias of the studies included single-centre designs (all studies), lim-
ited follow-up periods and a failure to provide mean effect changes nor any 
associated measures of random variability in the data analysis of relevant out-
comes. 
The strength of evidence was rated according to the GRADE Scheme for each 
outcome separately [65]. Each study was rated by two independent research-
ers. In case of disagreement a third researcher was involved to solve the dif-
ference. A more detailed list of criteria applied can be found in the recom-
mendations of the GRADE Working Group [65].  
GRADE uses four categories to rank the strength of evidence: 
 High = We are very confident that the true effect lies close  
to that of the estimate of the effect;  
 Moderate = We are moderately confident in the effect estimate: the 
true effect is likely to be close to the estimate of the effect, but there 
is a possibility that it is substantially different;  
 Low = Our confidence in the effect estimate is limited: the true effect 
may be substantially different from the estimate of the effect;  
 Very low = Evidence either is unavailable or does not permit  
a conclusion. 
The ranking according to the GRADE scheme for the research question can 
be found in the summary of findings table below and in the evidence profile 
in Appendix Table A-5 and Table A-6. 
Overall the strength of evidence for the effectiveness and safety of osteochon-
dral allograft transplantation in ankle joints in comparison to other surgical 
procedures is low or very low. The strength of evidence for the effectiveness 
and safety of osteochondral allograft transplantation in knee joints in com-
parison to other surgical procedures is very low. No evidence was identified 
for OCA for other joints. 
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Table 7-1: Summary of findings table of osteochondral allograft transplantation (ankle) 1 
Outcome 
Anticipated absolute effects (95% CI) 
Relative 
effect  
(95% CI) 
Number  
of patients  
(studies) 
Quality Comments 
Risk  
with OCA 
Risk with 
osteochondral 
autograft Difference 
EFFICACY 
Change in pain score  
Follow up: 2 years; assessed with: VAS;  
Scale from: 0 (less pain) to 10 (more pain) 
Mean 
reduction  
5.1 
Mean 
reduction  
5.7 
Mean difference 
0.6 
(p=0.15) 
Not  
estimable 
36 
(1 RCT) 
⨁⨁⨀⨀ 
LOW 2,3 
No significant difference identified, 
lower scores represent an 
improvement in pain 
Change in function score  
Follow up: 2 years; assessed with: FAAM; Scale 
from: 0 (worse function) to 100 (better function) 
Mean 
increase 
25.5 
Mean 
increase 
31.1 
Mean difference 
5.6 
(p=0.25) 
Not  
estimable 
36 
(1 RCT) 
⨁⨁⨀⨀ 
LOW 2,3 
No significant difference identified, 
higher scores represent an 
improvement in physical function 
Change in quality of life - - - - - - This outcome was not reported 
Total joint replacement - - - - - - This outcome was not reported 
SAFETY 4 
Procedure-related mortality (RCT) 
Follow up: 2 years 
0% 0% - Not  
estimable 
36 
(1 RCT) 
⨁⨁⨀⨀ 
LOW 2,3 There were no reported cases of procedure-related mortality 
Procedure-related mortality (single arm) 
Follow up: 2 years 
0% - - Not  
estimable 
17 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2,3 There were no reported cases of procedure-related mortality 
Complications (RCT) 
Follow up: 2 years 
18.8%  
(4.8 to 100) 
20.0% 1.4% fewer  
(15.2 fewer to  
92 more) 
RR 0.93 
(0.24 to 5.60) 5 
36 
(1 RCT) 
⨁⨁⨀⨀ 
LOW 2,3 
No significant difference identified, 
duration of follow-up was not 
adequate for this outcome 
Complications (single arm) 
Follow up: 4.1 (range 2-7) years 
5.9% 6 - - Not  
estimable 
17 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2,3 Duration of follow-up was not adequate for this outcome 
Transplant failure (RCT) 
Follow up: 2 years; assessed with:  
removal or replacement of the graft 
12.5% 
(2 to 79.2) 
10.0%  2.5% more  
(from 8 fewer 
to 69.2 more) 
RR 1.25  
(0.20 to 7.92) 5 
36 
(1 RCT) 
⨁⨁⨀⨀ 
LOW 2,3 No significant difference identified, duration of follow-up was not 
adequate for this outcome 
Transplant failure (single arm) 
Follow up: 4.1 (range 2-7) years; assessed with: 
removal or replacement of the graft 
29.4% - - Not  
estimable 
17 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2,3 None 
Abbreviations: CI = confidence interval, FAAM = foot and ankle disability measure, OCA = osteochondral allograft, RCT = randomised controlled trials, RR = relative risk,  
VAS = visual analogue scale. 
Comments: 
1 Only RCT data is presented in the summary of findings table, as this represents the highest level of evidence for this indication. Data from the included case series are presented in the appendix. 
2 There was a serious risk of bias due to inadequate randomization, allocation concealment, and blinding of patients and investigators. 
3 Sample size was below the optimal information size. 
4 In addition to the RCT, one case series was identified that investigated safety outcomes for ankle OCA.  
5 Calculated using MedCalc© (http://www.medcalc.org/calc/relative_risk.php) 
6 The reported complication may be underreported. In addition to reported complications, 4 of 17 patients (23.5%) required additional procedures (2 arthroscopic debridement, 2 arthrodesis). 
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Table 7-2: Summary of findings table of osteochondral allograft transplantation (knee) 1 
Outcome Anticipated absolute effects (95% CI) 
Relative 
effect  
(95% CI) 
Number  
of patients  
(studies) 
Quality Comments 
EFFICACY 
Pain: Change in pain score  
Follow up: 2 years; assessed with:  
KOOS – Pain Subscale; Scale from: 0 to 100 
Mean reduction in pain ranged from 15 to 26.5  
(p<0.05) 
Not  
estimable 
51 
(2 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Lower scores indicate 
improvement in pain 
Pain: Change in pain score  
Follow up: 2 years; assessed with:  
WOMAC – Pain Subscale; Scale from: 0 to 100 
Mean reduction in pain was 5.1  
(Pre-op: 91.0 ± 5.7 vs Post-op: 96.1 ± 4.6, 
p=0.002) 
Not  
estimable 
17 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Lower scores indicate 
improvement in pain 
Pain: Change in pain score  
Follow up: 2 years; assessed with: Modified 
Cincinnati knee rating score; Scale from: 0 to 100 
Mean reduction in pain was 10.6 
(Pre-op: 21.9 vs Post-op: 32.5, p<0.03) 
Not  
estimable 
23 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Lower scores indicate 
improvement in pain 
Function: Change in function score  
Follow up: range 1.9 to 4 years; assessed with: 
IKDC; Scale from: 0 to 100 
Mean increase in function ranged from  
16.5 to 17 
(p<0.03) 
Not  
estimable 
57 
(2 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Higher scores indicate 
improvement in physical 
function 
Function: Change in function score  
Follow up: 2 years; assessed with:  
WOMAC – Function Subscale; Scale from: 0 to 100  
Mean increase in function was 15 
(Pre-op: 68.1 ± 23.8 vs.Post-op: 83.1 ± 20.4, 
p=0.03) 
Not  
estimable 
17 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Higher scores indicate 
improvement in physical 
function 
Function: Change in function score 
Follow up: 2 years; assessed with:  
WOMAC – Overall; Scale from: 0 to 100 
Mean increase in function was 17.2 
(Pre-op: 65.1 ± 24.8 vs. Post-op: 82.3 ± 19.9, 
p=0.02) 
Not  
estimable 
17 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Higher scores indicate 
improvement in physical 
function 
Function: Change in function score  
Follow up: 1.9 to 4 years; assessed with: Modified 
Cincinnati Knee Rating Score – Function Subscale; 
Scale from: 0 to 100 
Mean increase in function was 9.2 
(Pre-op: 27.3 vs Post-op: 36.5, p<0.01) 
Not  
estimable 
23 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Higher scores indicate 
improvement in physical 
function 
Function: Change in function score  
Follow up: 1.9 to 4 years; assessed with: Modified 
Cincinnati Knee Rating Score – Overall Score;  
Scale from: 0 to 100 
Mean increase in function was 19.8 
(Pre-op: 49.2 vs Post-op: 69.0, p<0.02) 
Not  
estimable 
23 
(1 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Higher scores indicate 
improvement in physical 
function 
Function: Change in quality of life 
Follow up: 2 years; assessed with:  
KOOS – QoL Subscale; Scale from: 0 to 100 
Mean increase in quality of life ranged from  
25 to 30.6 (p<0.001) 
Not  
estimable 
51 
(2 case series) 
⨁⨀⨀⨀ 
VERY LOW 2 
Higher scores indicate 
improvement in quality of life 
Necessity of total joint replacement 
Follow up: 0.3 to 14.5 years 3 
Overall 5.6% (7/125) Not  
estimable 
125 
(2 case series) 
⨁⨀⨀⨀ 
VERY LOW 2,4 
Liimted data to assess this 
outcome 
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Outcome Anticipated absolute effects (95% CI) 
Relative 
effect  
(95% CI) 
Number  
of patients  
(studies) 
Quality Comments 
SAFETY 
Procedure-related mortality 
Follow up: range 0.3 to 14.5 years 3 
0.0% (0/165) Not  
estimable 
165 
(4 case series) 
⨁⨁⨀⨀ 
LOW There were no reported cases of procedure-related mortality 
Complications  
Follow up: range 0.3 to 14.5 years 3 
Overall complications: 12.7% (21/165) 
(range 4.3%% to 26.5%) 
Not  
estimable 
165 
(4 case series) 
⨁⨀⨀⨀ 
VERY LOW 2,4,5 
None 
Transplant failure  
Follow up: 2 years; assessed with:  
removal or replacement of the graft 
Overall transplant failures: 7.8% (4/51) 
(range 7.0% to 11.8%) 
Not  
estimable 
51  
(2 case series) 
⨁⨀⨀⨀ 
VERY LOW 2,4 
None 
Abbreviations: KOOS = Knee injury and Osteoarthritis Outcome Score, OCA = osteochondral allograft, RCT = randomised controlled trials, VAS = visual analogue scale. 
Comments: 
1 P values should be interpreted with caution due to small sample size without a comparative assessment. 
2 Sample size was below the optimal information size. 
3 A very small proportion of patients in one study had follow-up less than 2 years. 
4 Follow-up length was insufficient to properly measure the necessity for joint replacement. 
5 Large degree of variation in reported adverse event rates across studies. 
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8 Discussion 
Osteochondral lesions commonly effect the knee or ankle joint [50]. Typically, 
these lesions appear following repetitive strain or direct trauma; often owing 
to a sporting injury. 
Symptoms of pain, swelling, catching and locking of the joint may all contrib-
ute to debilitation and interfere with one’s ability to carry out their activities 
of daily living. Further, it may cause discomfort, and potentially lead to the 
progression of osteoarthritis. 
Osteochondral allograft transplantation (OCA) is one therapeutic option to 
treat such defects, including medium to large defects >3cm2 of the knee or 
large lesions of the ankle [49, 62]. Surgical treatment of ankle or knee lesion 
seeks to restore function, relieve pain, induce the healing of bone and dam-
aged cartilage and/or avoid the need for total knee arthroplasty (TKA) in 
young patients, who respond poorly to TKA [30, 49]. 
The aim of this systematic review was to evaluate the safety and effectiveness 
of OCA compared to alternate surgical approaches for patients with an osteo-
chondral lesion who have failed conservative management or primary surgery. 
Evidence which met the inclusion criteria for this review was found to per-
tain exclusively to patients with osteochondral lesions in the knee or ankle. 
 
Interpretation of findings 
Study quality, validity and overall level of evidence 
Ankle 
One included study compared osteochondral allograft to osteochondral auto-
graft transplantation as a treatment for osteochondral lesions of the talar dome 
[57]. This study was intended to inform the recommendation based on clini-
cal effectiveness however, it was classified as having a high risk of bias and 
thus all results should be considered with caution. 
The RCT reported post-operative pain and functionality scores and provided 
a p-value for comparison between the two trial arms. Neither pain nor func-
tionality post-operatively was significantly different between groups. The 
study did not report mean changes between pre- and post-operative scores. It 
is unclear whether decreases in pain and increases in functionality in either 
treatment arm were significant. 
Neither the efficacy nor comparative effectiveness of OCA is clear from the 
available evidence. It would appear post-surgical pain and function is com-
parable between osteochondral allograft and autograft transplants. However, 
it needs to be established whether there is a significant (statistically or clini-
cally) change in pain and functionality outcomes following surgical interven-
tion and whether this varies between OCA, autograft transplants and other 
surgical interventions (e.g. autologous chondrocyte implantation or mosaic-
plasty) [49]. 
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Again, the RCT provided the only comparative safety data for OCA relative 
to an appropriate comparator (i.e. osteochondral autograft transplant). The 
need for revision operations due to graft non-unions was similar regardless of 
treatment assignment. Of note, 30% of the autografts led to donor site mor-
bidity (i.e. knee complications). Such complications were avoided in the OCA 
group. 
An additional, case-series was included in the safety assessment; however, 
this study was identified as having a moderate risk of bias. Five of 17 grafts 
were considered a ‘failure’, and a further 2 were considered ‘poor’ due to the 
need for post-transplant arthroscopic debridement. 
A recently published systematic review drew the conclusion that OCA may 
improve functional status in patients with large lesions of the talus however, 
the associated risk of failure, re-operation, or revision surgery is relatively 
high [66]. This review, however, relied solely on small (n ≤ 38), prospective 
case series. 
The comparative safety of OCA to all relevant comparators remains uncertain. 
Knee 
No comparative studies comparing OCA to a relevant comparator for oste-
ochondral defects of the knee were retrieved. Four prospective case-series were 
included to inform the effectiveness recommendation for OCA therapy for de-
fects of the knee [58-61]. 
Knee-specific measurement tools were used by three of the four studies to 
elicit patient-reported measures of pain, functionality and quality of life out-
comes. The remaining study, which was identified as having a severe risk of 
bias, provided no patient-reported outcome measures. It did, however, report 
known number of subsequent total knee arthroscopies undergone which was 
of relevance. 
Based on the available evidence it would seem OCA has significant (statisti-
cally) effect of pain, functionality and quality of life; however, this observation 
should be considered cautiously given it is based solely on small, prospective 
case series and provides no comparative assessment. 
Recent systematic reviews support the notion that clinical outcomes improve 
following OCA surgery; however, a significant portion of the evidence inform-
ing the conclusions drawn in these reviews is retrospective [1, 2, 67]. 
The same four case series referred to for the effectiveness evaluation of OCA 
in knee patients also informed the safety evaluation. Adverse events are re-
ported; however, it is difficult to judge whether this provides a comprehensive 
safety profile of OCA. Namely because only one study specified that compli-
cations were monitored. 
Relevance of the outcomes assessed to the potential  
patient-relevant benefits 
Effectiveness outcomes assessed during this review include pain, functional-
ity, quality of life, activities of daily living/sport and necessity of total joint 
replacement. This suite of outcomes was thought sufficient to capture patient-
relevant benefits of OCA. 
Effectiveness in ankle patients in the single RCT was measured using the 
FAAM for overall functionality and a 10-point VAS to measure patient-per-
ceived pain. 
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Various knee-specific, patient-reported tools were employed to measure symp-
toms, functionality and quality of life outcomes. These included the KOOS, 
the WOMAC, the IKDC and the Modified Cincinnati Knee Rating System. 
Some of these tools are measured with patient-completed questionnaires, which 
involve a level of subjectiveness. The applicability of the included studies, in-
cluding population, interventions, comparators and outcomes, is outlined in 
the Appendices (See Appendix Table A-7).  
The responsiveness of the IKDC and the WOMAC to changes following sur-
gical interventions has been demonstrated [51]. 
Both the KOOS and the WOMAC capture disaggregated component scores, 
which is of benefit when interpreting results [51]. The KOOS sports and rec-
reation subscale may not be applicable for less physically active patients, al-
though it is commonly active individuals at risk of OCAs. However, the func-
tion scale of the WOMAC may not be comprehensive for physically active 
patients as it lacks difficult functional tasks. 
The Cincinnati Knee Rating system has been shown reliable in both unin-
jured patients and those seeking treatment for knee-related problems how-
ever, a “modified” scale was used by the included study in this report which 
may not be appropriately reflective of the original scale [68]. 
Evidence gaps and ongoing studies 
This systematic review identified a lack of comparative data for OCA. Con-
sidering this sparsity, it remains difficult to comprehensively understand the 
benefits and risks associated with OCA. 
A single RCT, restricted to osteochondral lesions of the talar dome was re-
trieved. This study had a high risk of bias, and an overall sample size of only 
40 patients. Moreover, it was necessary to rely solely on prospective, single-
arm studies to inform a recommendation for the use of OCA for osteochon-
dral knee defects despite the knee being a common site of such defects. 
In addition, there are no registered, active, ongoing trials that intend to com-
pare OCA to a relevant comparator (see Appendix Table A-8). 
Greater comparative evidence for OCA relative to both autografts and other 
potential surgical approaches, and across both ankle and knee populations is 
essential to reach a better-informed recommendation. 
Limitations in the report 
This report encountered limitations regarding the available evidence base. 
As outlined in the pre-defined PICO criteria, only the highest level of evidence 
was considered for each indication. For ankle lesions, this meant a single RCT 
formed the evidence based to inform the effectiveness recommendation. Pro-
spective case-series were included to inform the safety recommendation, how-
ever, only one additional study was retrieved. For knee lesions, only prospec-
tive case-series studies were identified. For both indications, there was a dis-
tinct lack of prospective, comparative data. The studies that were identified 
had small sample sizes, or follow-up times that were too short to detect im-
portant effects. Further, effectiveness outcomes were reported by different 
scoring systems, thereby limiting the ability to compare data across studies. 
Finally, five studies were excluded based on small sample size (n<15) [69-
73]. These studies reported relevant safety outcomes, but did not identify any 
complications not already identified in the included studies.  
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subjektiv 
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lediglich 1 RCT zum 
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The exclusion of retrospective study designs limited the evidence base ob-
tained in this review; however, this decision was justified given the validity 
concerns of retrospective designs. Retrospective studies were excluded from 
this review for several reasons. First, it is unclear whether all relevant out-
comes were collected (e.g. failures, adverse events), or if they were recorded 
comprehensively in clinical databases. Some patients may have left the care 
of the institution and had a failure or adverse event elsewhere that may not 
be captured in these studies. Second, follow-up times vary greatly between 
patients in retrospective trials, and results are often reported at last follow-
up. This is particularly problematic for reported graft survival rates, where-
by the last-observation-carried-forward method has been used to extrapolate 
survival findings of all patients to the longest follow-up time in the study [74]; 
for example, the majority of patients had a follow-up of only 2 years, but graft 
survival was extrapolated over 22 years of follow-up based on the longest-
treated patient, thereby presenting distorted estimates of graft survival rates. 
For these reasons, only prospective studies were included in this review. 
 
Conclusion 
A comprehensive understanding of the comparative risks and benefits of OCA 
compared to other forms of surgical management for osteochondral defects 
of the knee or ankle joint is not possible based on the currently available ev-
idence. Very little comparative data was found, and where it was available, 
this was a single study, and was limited to patients with osteochondral lesions 
of the talar dome. Single-arm studies made up much of the evidence based 
available upon which to build a recommendation. At this stage, the compar-
ative clinical effectiveness and safety of OCA relative to other surgical ap-
proaches remains unclear.  
 
Ausschluss 
retrospektiver Studien 
(Unklarheit über 
umfassende Erhebung 
relevanter Endpunkte, 
Nachbeobachtungszeit-
räume variieren stark) 
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Wirksamkeit und 
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Vergleich zu anderen 
Interventionen 
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9 Recommendation 
In Table 9-1 the scheme for recommendations is displayed and  
the according choice is highlighted. 
Table 9-1: Evidence based recommendations 
 The inclusion in the catalogue of benefits is recommended.  
 The inclusion in the catalogue of benefits is recommended with restrictions. 
 The inclusion in the catalogue of benefits is currently not recommended. 
X The inclusion in the catalogue of benefits is not recommended. 
 
Reasoning: 
The current evidence is insufficient to prove that the assessed technology is 
at least as effective and safe than the comparators for knee and other joints. 
New study results will potentially influence the effect estimate considerably; 
however, there does not appear to be any ongoing clinical trials that will add 
further information in the near future. 
On the basis of the limited evidence demonstrating a benefit of OCA in com-
parison to osteochondral autograft transplantation for knee and other joints, 
as well as the lack of ongoing trials, the inclusion in the hospital benefit cat-
alogue is not recommended. 
 
 
keine ausreichend 
robuste Evidenz 
Aufnahme  
nicht empfohlen 
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Appendix 
Evidence tables of individual studies included  
for clinical effectiveness and safety 
Table A-1: Osteochondral allograft transplantation: Results from randomised controlled trials (ankle) 
Author, year Ahmad et al 2016 
Country USA  
Sponsor None 
Intervention/Product OCA 
Comparator Osteochondral autograft 
Study design RCT 
Number of pts 40 (I. 20 vs C: 20)1 
Inclusion criteria Recurrent OLT that failed initial arthroscopic treatment or large (≥1.5cm2) OLT, 
Failed recent nonoperative treatment, with a minimum  
4 weeks NWB immobilisation, 
OLT does not involve the (medial or lateral) shoulder of the talar dome, 
Amenable to operative treatment with osteochondral plugs 
Age of patients (yrs)  
[mean (range)] 
I. 39.7 (17-60) 
C. 41.3 (14–63) 
Gender, male % I. 62.5%* 
C. 55.0%* 
Number of prior surgeries per patient NR 
Indication (%) Osteochondral lesions of the talar dome (OLT) 
100% 
Concurrent procedures (%) NR 
Mean graft storage time, days NR 
Chondral lesion size (range) I. 1.8cm2 (0.7-4.2) 
C. 1.6 cm2 (0.7-2.4) 
Transplanted location (%) I: 
Anterior or central OLT (87.5%*) 
Posteromedial (12.5%*) 
C: 
Anterior or central OLT (80.0%*) 
Posteromedial (20.0%*) 
Follow-up, years (range) I. 3.4 (1.2-6.4)* 
C. 2.9 (1–5.4)* 
Loss to follow-up, n (%) I: 4 (20%*)2  
C: 0 (0%) 
                                                             
1 Total number randomised. An ITT study design was not employed; number of patients used when reporting  
patient characteristics and in subsequent analyses was 36 (I:16 vs. C: 20) 
2 Four patients in the intervention arm were excluded intra-operatively as they were discovered to have significant 
involvement of either the medial or lateral shoulder of the talar dome. 
Osteochondral allograft transplantation for the knee (or other joints) 
60 LBI-HTA | 2019 
Author, year Ahmad et al 2016 
Outcomes 
Efficacy 
Decrease in pain 
 VAS 
mean (range) 
I vs. C 
Preoperative 
7.8/10 (5-10) vs. 7.9/10 (4-10) 
Post-operative 
2.7/10 (1-8) vs. 2.2/10 (0-8) 
p=0.15 
Increase in functionality 
 FAAM 
mean (range) 
I vs. C 
Preoperatively 
55.2/100 (36.9-82.1)  
vs. 54.4/100 (31.0-88.1)  
Postoperatively 
80.7/100 (56.0-95.2)  
vs. 85.5/100 (56.0-97.6) 
p=0.25 
Increase in quality of life NR 
Necessity of total joint replacement NR 
Return to daily/sports/physical activities NR 
Safety 
Procedure-related mortality 0 (0%) 
Adverse events  
n (%) 
I vs. C 
graft nonunion 
3 (18.8%) vs. 2 (10.0%) 
postoperative superficial wound blistering  
0 (0%) vs 1 (5.0%) 
postoperative knee complications  
0 (0%) vs. 6 (30.0%) 
anterior ankle arthritis 
1 (6.3%) vs. 0 (0%) 
Transplant failure rates I vs. C 
graft nonunion requiring removal3 
2 (18.8%) vs. 2 (10.0%) 
Re-admission NR 
Re-operation/additional surgery I vs. C 
Conversion to alternate treatment3 
2 (12.5%) vs. 2 (10.0%) 
Abbreviations: OCA = osteochondral allograft transplantation, OLT = osteochondral lesion of the talar dome,  
RCT = randomised controlled trial, FAAM = foot and ankle ability measure, VAS = visual analogue scale. 
Notes: *calculations made during extraction 
 
 
                                                             
3 Two patients in the intervention arm had their allograft converted to an autograft as revision operative treatment; 
two patients in the comparator arm had their autograft converted to talar allograft plugs as revision operative 
treatment. At six months post-revision surgery, all patients had achieved full osteochondral healing on radio-
graphic and CT imaging.  
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Table A-2: Osteochondral allograft transplantation: Results from observational studies of osteochondral allograft transplant (knee and ankle) 
Author, year Brown et al 2011 Cinats et al 2018 LaPrade et al 2009 Mahomed et al 1992  Haene et al 2012 4 
Country USA Canada USA Canada Canada 
Sponsor AlloSource Inc., Centennial, 
Colorado 
Calgary Health Trust None NR None 
Intervention/Product OCA OCA OCA OCA OCA 
Comparator N/A N/A N/A N/A N/A 
Study design Prospective case series Prospective case series Prospective case series Prospective case series Prospective case series5 
Number of pts 34 17 6 23 91 16 
Transplant for knee or ankle Knee Knee Knee Knee Ankle 
Inclusion criteria Grade 4 International 
Cartilage Repair Society 
(ICRS) articular cartilage 
defects 
Age 18-50, 
presence of 80% meniscus, 
no inflammatory arthropathy, 
no osteoarthritis, 
no Workers Compensation 
Board cases 
Symptomatic full-thickness 
articular cartilage defect of >3cm2, 
no so-called kissing lesion of 
the corresponding articular 
cartilage surface, 
less than minor peripheral 
osteophytes or joint-space 
narrowing, 
no ligamentous instability, 
no malalignment, 
presence of >50% of the 
meniscus in the ipsilateral 
compartment 
Posttraumatic 
osteoarticular defect  
of the knee joint 
Undergoing fresh allograft 
transplantation for a talar 
lesion 
Age of patients, yrs (range)  34.5 (15-61) 33 (17-45) 30.9 (16.4-46.9) 41.9 (17-75) 35.8 (15-53) 
Gender, male % 74.0% 47.1% 56.5%* 56.0%* 50.0% 
Number of prior surgeries 
per patient 
0.7 1.2*7 1.7 NR 16 of 17 ankles had 
undergone single or  
mutliple surgeries  
                                                             
4 Haene et al. (2012) included for safety data only as an RCT for ankle patients was available. 
5 Potentially retrospective, although given the ambiguity this was left in.  
6 Three patients with shoulder transplants were excluded from the data extraction.  
Data pertaining to outcome measures reported for knee and shoulder patients combined was not extracted (VAS and SF-36 scores). 
7 Calculated, 20 procedures from 17 knee patients 
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Author, year Brown et al 2011 Cinats et al 2018 LaPrade et al 2009 Mahomed et al 1992  Haene et al 2012 4 
Indication (%) Avascular necrosis (5.0%) 
Osteochondritis dissecans 
(31.0%) 
Focal osteoarthritis defects 
(64.0%)8 
NR Localized osteochondral lesion 
due to a dislodged osteochon-
dritis dissecans lesion of the 
femoral condyle (60.9%*) 
Localized full-thickness 
chondral defects (39.1%*) 
Posttraumatic 
osteoarticular defect of 
the knee joint (100%) 
Talar lesion (100%) 
Concurrent procedures (%) Anterior cruciate ligament 
reconstruction (2.9%*) 
Tibial realignment osteotomy 
(14.7%*) 
Medial patellofemoral 
ligament reconstruction 
(2.9%*) 
Meniscus transplant (5.9%*)9 
NR Proximal tibial osteotomy 
(30.4%*) 
Meniscal transplant (13.0%*) 
Partial posterior horn medial 
meniscectomy (4.3%*) 
Concurrent Herbert screw 
removal (4.3%*) 
Concurrent revision  
anterior cruciate ligament 
reconstruction additional to 
meniscal transplant (4.3%*) 
NR NR 
Mean graft storage time, 
days (range) 
21.1 (16-26) 10.6 (3-18) 20.3 (15-25) NR NR 
Chondral lesion size (range) 5.7 (1.5-15) cm2 2.6* (2.0-3.4) cm diameter 4.8 (3.1-9.6) cm2 NR At least one dimension 
>15mm10 
Transplanted location (%) Femoral condyle (100%) Lateral tibial plateau (17.6%*) 
Lateral femoral condyle (41.2%*) 
Medial femoral condyle 
(41.2%*) 
Medial femoral condyle 
(82.6%*) 
Lateral femoral condyle (13.0%*) 
Both medial and lateral (4.3%*) 
NR Posteromedial talar (64.7%*) 
Medial talar (17.6%*) 
Posterolateral talar (11.8%*) 
Anterolateral talar (5.9%*) 
Follow-up, years mean, 
(range) 
2 2 3 (1.9 to 4)11 5.7* 
(0.3 – 14.5*)12 
4.1 (2-7) 
Loss to follow-up, n (%) 10 (29.4%)13 0 (0%) 0 (0%) 28 (30.8%*)14 0 (0%) 
                                                             
  8 Information presented in the written text and table differed. Indications reported in the written text were extracted, 
  9 Information presented in the written text and in the table differed. Concurrent procedures reported in the written text were extracted. Total number of patients  
receiving concurrent interventions (n=9) was the same in both the written text and the table. Percentages calculated using patient number (n=34) as denominator.  
10 For all except one lesion, whose diameter was between 10-15mm and which had failed prior autograft transplantation 
11 Three patients did not have 2-year follow-up data however, all three reported their knees felt normal so did not want to return for a follow-up exam.  
12 It is unclear how many patients had a follow-up of less than 2 years, 
13 Applies for a follow-up period of 2-years. 3 patients moved, 1 was converted to a total knee arthroplasty and 6 were lost for unknown reasons. 
14 23 patients could not be contacted by phone, 5 patients died due to causes unrelated to the procedure.  
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Author, year Brown et al 2011 Cinats et al 2018 LaPrade et al 2009 Mahomed et al 1992  Haene et al 2012 4 
Outcome 
Efficacy 
Decrease in pain 
 KOOS  
(pain) 
Baseline vs. 2-year follow-up 
59 (± 17) vs. 74 (± 22) 
p=0.028 
Preoperative vs. 2-years 
postoperative 
52.5 (± 24.3) vs. 79.0 (± 20.53) 
p<0.001 
NR NR  
 WOMAC  
(pain) 
NR Preoperative vs. 2-years 
postoperative 
91.0 (± 5.7) vs. 96.1 (± 4.6) 
p=0.002 
NR NR  
 Modified Cincinnati 
knee-rating score  
(symptoms) 
NR NR Baseline vs. follow-up15 
21.9 vs 32.5 
p<0.03 
NR  
Increase in functionality 
 IKDC Questionnaire Baseline vs. 2-year follow-up 
45 (± 11) vs. 62 (± 20) 
p<0.00157 
NR Baseline vs. follow-up15 
52.0 vs. 68.5 
p<0.03 
NR  
 WOMAC 
(function) 
NR Preoperative vs. 2-years 
postoperative 
68.1 (± 23.8) vs. 83.1 (± 20.4) 
p=0.03 
NR NR  
 WOMAC 
(overall) 
NR Preoperative vs. 2-years 
postoperative 
65.1 (± 24.8) vs. 82.3 (± 19.9) 
p=0.02 
NR NR  
 Modified Cincinnati 
knee-rating score 
(function) 
NR NR Baseline vs. follow-up15 
27.3 vs. 36.5 
p<0.01 
NR  
 Modified Cincinnati 
knee-rating score 
(overall) 
NR NR Baseline vs. follow-up15 
49.2 vs 69.0 
p<0.02 
NR  
                                                             
15 Data collected at final clinical follow-up was compared to preoperative data. No specified post-operative data collection interval is specified. 
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Author, year Brown et al 2011 Cinats et al 2018 LaPrade et al 2009 Mahomed et al 1992  Haene et al 2012 4 
Increase in quality of life 
 KOOS 
(QoL) 
Baseline vs. 2-year follow-up 
23 (± 17) vs. 48 (± 22) 
p<0.001 
Preoperative vs. 2-years 
postoperative 
20.6 (± 15.4) vs. 51.2 (± 31.1) 
p=0.001 
NR NR  
Necessity of total joint 
replacement (n) 
n=1 NR NR n=6  
Return to daily/sports/physical activities 
 KOOS  
(acitivities of daily living) 
Baseline vs. 2-year follow-up 
69 (± 21) vs. 83 (± 23) 
p=0.058 
Preoperative vs. 2-years 
postoperative 
68.5 (± 24.3) vs. 84.8 (± 19.9) 
p=0.004 
NR NR  
 KOOS  
(sports and recreation) 
Baseline vs. 2-year follow-up 
37 (± 26) vs. 57 (± 30) 
p=0.005 
Preoperative vs. 2-years 
postoperative 
21.2 (± 22.0) vs. 54.4 (± 31.9) 
p=0.002 
NR NR  
Safety 
Procedure-related mortality 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Adverse events  
 peri- and post-operative, 
n(%)  
On arthroscopic investigation:16 
Fibrosis impinging adjacent 
meniscus (n=1) 
ICRS grade 2/3 changes in trans-
planted graft cartilage (n=2) 
Fragmentation or 
delamination of the graft with 
associated loose bodies (n=3) 
Minimal fraying (n=3) 
DVT and pulmonary 
embolism:  
n=1 (5.9%*) 
Edema, fragmentation at the 
interpositional interface with 
delamination of the articular 
cartilage.17  
n=2 (11.8%) 
Superficial cellulitis:  
n=1 (4.3%*) 
Stifness requiring 
manipulation (n=3)  
Reflex sympathetic 
dystrophy (n=1)  
Wound hematoma (n=1)  
Rupture of the patellar 
tendon (n=1)  
Respitory (n=2)18 
Malunion of a medial 
malleolar osteotomy site 
(n=1)19 
                                                             
16 In patients who had a subsequent procedure, transplanted grafts were evaluated arthroscopically. 14 patients had a subsequent procedure,  
9 of which were directly related to the OCA transplant.  
17 Found on MRI and secondary arthroscopy in the 2 patients whose grafts were considered ‘failures’ (i.e. ongoing pain and debilitation). 
18 Number only, no %, reported. Calculations were not made as it was unclear what the denominator should be.  
19 This did not require additional treatment. 
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Author, year Brown et al 2011 Cinats et al 2018 LaPrade et al 2009 Mahomed et al 1992  Haene et al 2012 4 
Transplant failure rates, n(%) n=220 (7%)  n=2 (11.8%*) NR NR21 5 of 17 ankles (29.4%*) 
Re-admission NR NR NR NR NR 
Re-operation/additional 
surgery 
Procedure directly related  
to OCA: (n=9)  
Procedure unrelated to OCA: 
(n=5) 
Second arthroscopy (after 
transplant failure):  
n=2 (11.8%*)  
Removal of symptomatic hard-
ware from a concurrent proximal 
tibial opening n=3 (13.0%) 
Diagnostic arthroscopy (after 
valgus twisting injury) 
n=1 (4.3%*) 
Lateral patellotibial ligament 
reconstruction n=1 (4.3%*) 
Total knee arthroplasty 
(n=6) 
Arthrodesis (n=3) 
Re-transplant (n=3) 
Curetage and drilling: 
(n=1)22  
Arthroscopic debridement 
2 of 17 ankles (11.8%*)  
Arthrodesis 
2 of 17 ankles (11.8%*)  
Abbreviations: FAAM = foot and ankle ability measure, ICRS = International Cartilage Repair Society, IKDC = International Knee Documentation Committee,  
KOOS = Knee injury and osteoarthritis outcome score, N/A = not applicable, NR = not reported, OCA = osteochondral allograft, OCT = osteochondral lesion of the talar dome,  
VAS = visual analogue scale, WOMAC = Western Ontario and McMaster Universities Osteoarthritis index. 
* Own calculations. 
 
 
Risk of bias tables and GRADE evidence profile 
Internal validity of the included studies was judged by two independent researchers. In case of disagreement a third researcher was involved to solve the differ-
ences. A more detailed description of the criteria used to assess the internal validity of the individual study designs can be found randomised comparative trial 
can be found from the Cochrane Collaboration [5] and in the Guidelines of EUnetHTA [75]. Single arm studies were appraised according to the IHE appraisal 
tool for case series studies [6]. 
Table A-3: Risk of bias – study level (randomised studies for knee), see [5] 
Trial 
Adequate generation  
of randomisation sequence 
Adequate allocation 
concealment 
Blinding Selective outcome 
reporting unlikely 
No other aspects which 
increase the risk of bias 
Risk of bias – 
study level Patient Treating Physician 
Ahmad et al, 2016 [57] No No No No Yes Yes High 
                                                             
20 This number is based on 30 patients who were evaluated by CT scan. 
21 % successful transplants at 5, 10- and 14-years post transplantation was presented however, it is unclear how many patients were included in the calculations  
at each time point. The information presented was considered very misleading and was therefore not extracted.  
22 Presented as number of patients only, not %, as it was unclear at what stage in follow up these occurred i.e. what the denominator should be  
(original sample, or exclude those lost to follow up) 
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Table A-4: Risk of bias – study level (case series for knee and ankle), see [6] 
Study  
reference/ID 
Brown et al  
2011 
Cinats et al  
2018 
LaPrade et al 
2009 
Mahomed et al 
1992 
Haene et al  
2012 
Study objective 
1. Was the hypothesis/aim/objective of the study clearly stated in the abstarct, introduction or 
methods section? 
Yes Yes Yes Yes Yes 
Study design 
2. Was the study conducted prospectively? Yes Yes Yes Unclear23 Yes 
3. Were the cases collected in more than one centre? No No No No No 
4. Were patients recruited consecutively? Unclear Unclear Yes Unclear Unclear 
Study population 
5. Were the characteristics of the patients included in the study described?  Yes Yes Yes Partial24 Yes 
6. Were the eligibility criteria (i.e. inclusion and exclusion criteria) for entry into the study 
clearly stated? 
No25 Yes Yes No26 No27 
7. Did patients enter the study at a similar point in the disease?28 Yes Yes Yes29 Unclear Yes 
Intervention and co-intervention 
8. Was the intervention of interest clearly described? Yes Yes Yes Yes Yes 
9. Were additional interventions (co-interventions) clearly described?30 Yes No Yes No No 
                                                             
23 Patients receiving fresh osteochondral allografts via the Bone Bank Program have been prospectively followed since 1972. Mahomed et al. (1992) report outcomes for a subgroup 
of patients (i.e. those whose osteochondral defect is due to trauma) in whom, on review of the first 100 cases. There is a possibility this is a post-hoc analysis  
24 Previous surgeries undergone are not reported. 
25 Exclusion criteria (i.e. ineligibility for an allograft transplant) not specified. 
26 Inclusion/exclusion criteria for the Blood Bank Program (from which patients are taking part in) is not reported. 
27 Exclusion criteria (i.e. ineligibility for a fresh allograft transplant) not specified. 
28 Grade of cartilage defect. Where this was not reported, lesion size was then considered. 
29 All lesions were symptomatic full-thickness articular cartilage defects of >3cm2.  
30 Concurrent procedures were considered when answering this question.  
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Study  
reference/ID 
Brown et al  
2011 
Cinats et al  
2018 
LaPrade et al 
2009 
Mahomed et al 
1992 
Haene et al  
2012 
Outcome measures 
10. Were relevant outcome measures established a priori? Yes Yes Yes Yes Yes 
11. Were the relevant outcomes measured using appropriate objective/subjective methods?31 Yes Yes Yes No32 Yes 
12.Were the relevant outcome measures made before and after the intervention? Yes Yes Yes Unclear33 Yes 
Statistical Analysis 
13.Were the statistical tests used to assess the relevant outcomes appropriate? Yes Yes Yes No34 Yes 
Results and Conclusions 
14.Was follow-up long enough for important events and outcomes to occur?35 No No No Yes Yes 
15. Were losses to follow-up reported? Yes Yes Yes Yes Yes 
16.Did the study provided estimates of random variability in the data analysis of relevant 
outcomes? 
No36 No37 No No No 
17.Were the adverse events reported? Yes Yes Yes Yes   
18.Were the conclusions of the study supported by results? Yes Yes Yes Unclear38 Yes 
Competing interests and sources of support 
19.Were both competing interests and sources of support for the study reported? Yes Yes Yes No Unclear39 
Overall Risk of bias Moderate Moderate Low Serious Moderate 
Notes: with regard to the number of yes responses: 1-7 was considered indicative of serious risk of bias, 8-14 of moderate risk and 15-19 of low.  
 
  
                                                             
31 Where routine follow-ups were specified in the methods section, it was assumed that the intent was to monitor both outcomes and complications at these visits.  
32 The method for capturing complications was not adequately reported in the methods section. 
33 Pre-surgical assessment is not explicated described, although failure is described as an increment in the post-operative knee score, implying a comparison to a pre-operative score. 
34 Survivorship analysis extrapolating follow-up of all patients to the longest follow up time of a single patient, does not account for censoring correctly. 
35 Mean follow-up of 4 years was considered reasonable. 
36 Variability in the mean difference was not reported, only a p-value.  
37 Variability in the mean difference was not reported, only a p-value. 
38 Many conclusions are summarised at the closure of the article. These are not all supported by, or relevant to, the results presented. 
39 Potential conflict of interest noted, although the conflicting party not identified (in the available disclosure statement). 
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Table A-5: Evidence profile: efficacy and safety of osteochondral allograft transplantation (ankle) 
Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies Study design Risk of bias Inconsistency Indirectness Imprecision 
Other  
considerations OCA 
Autologous 
autograft 
Relative  
(95% CI) 
Absolute  
(95% CI) 
Efficacy 
Pain: change in pain score (Follow up: 2 years; assessed with: VAS; Scale from: 0 (less pain) to 100 (more pain)) 
1 RCT serious 1 N/A  
(only one trial) 
not serious serious 2 none 16 20 -  ⨁⨁⨀⨀ 
LOW 
Function: Change in function score (follow up: 2 years; assessed with: FAAM; Scale from: 0 (worse function) to 100 (better function)) 
1 RCT serious 1 N/A  
(only one trial) 
not serious serious 2 none 16 20 -  ⨁⨁⨀⨀ 
LOW 
Function: Change in quality of life (outcome not reported) 
- - - - - - - - - - - - 
Necessity of total joint replacement (outcome not reported) 
- - - - - - - - - - - - 
Safety 
Procedure-related mortality (follow up: 2 years) 
1 RCT serious 1 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
0/16 0/20 not esimtable - ⨁⨁⨀⨀ 
LOW 
Procedure-related mortality (follow up: 2 to 7 years) 
1 Case series serious 3 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
0/16 - - - ⨁⨀⨀⨀ 
VERY LOW 
Complications (follow up: 2 years) 
1 RCT serious 1 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
3/16  
(18.8%) 
4/20  
(20.0%) 
RR 0.93 
(0.24 to 5.60) 
14 fewer per 1,000 
(from 152 fewer to 
920 more) 
⨁⨁⨀⨀ 
LOW 
Complications (follow up: 2 to 7 years) 
1 Case series Serious 3 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
1/17 ankles 
(5.9%) 
- - - ⨁⨀⨀⨀ 
VERY LOW 
Transplant failure (follow up: 2 years; assessed with: removal or replacement of the graft) 
1 RCT serious 1 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
2/16  
(12.5%) 
2/20  
(10.0%) 
RR 1.25  
(0.20 to 7.92) 
25 more per 1,000 
(from 80 fewer to 
692 more) 
⨁⨁⨀⨀ 
LOW 
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Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies Study design Risk of bias Inconsistency Indirectness Imprecision 
Other  
considerations OCA 
Autologous 
autograft 
Relative  
(95% CI) 
Absolute  
(95% CI) 
Transplant failure (follow up: 2 to 7 years; assessed with: removal or replacement of the graft) 
1 Case series Serious 3 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
5/17 ankles 
(29.4%) 
- - - ⨁⨀⨀⨀ 
VERY LOW 
Re-admission (outcome not reported) 
- - - - - - - - - - - - 
Re-operation (Follow up: 2 years; assessed with: any follow-up procedure on the treated joint) 
1 RCT serious 1 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
2/16  
(12.5%) 
2/20  
(10.0%) 
RR 1.25 
(0.20 to 7.92) 
25 more per 1,000 
(from 80 fewer to 
692 more) 
⨁⨁⨀⨀ 
LOW 
Re-operation (follow up: 2 to 7 years; assessed with: any follow-up procedure on the treated joint) 
1 Case series Serious 3 N/A  
(only one trial) 
not serious serious 2 Follow-up 
duration too short 
4/17 ankles 
(23.5%) 
- - - ⨁⨀⨀⨀ 
VERY LOW 
Abbreviations: CI = confidence interval, N/A = not applicable, OCA = osteochondral allograft transplantation, RCT = randomized controlled trial, RR = relative risk.  
Comments: 
1 There was a serious risk of bias due to inadequate randomization, allocation concealment, and blinding of patients and investigators. 
2 Sample size is below optimal information size. 
3 Eligibility criteria were unclear, additional co-interventions were not reported, no estimates of random variability were reported, method for capturing complications were not reported. 
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Table A-6: Evidence profile: efficacy and safety of osteochondral allograft transplantation (knee) 
Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies Study design Risk of bias Inconsistency Indirectness Imprecision 
Other  
considerations OCA 
Other surgical 
procedure 
Relative  
(95% CI) 
Absolute  
(95% CI) 
Efficacy 
Pain: change in pain score (follow up: 2 years; assessed with: VAS; Scale from: 0 (less pain) to 100 (more pain)) 
2 Case series not serious not serious not serious serious 1 none 51 - - Mean reduction in pain 
ranged from 15 to 26.5 
(p<0.05) 
⨁⨀⨀⨀ 
VERY LOW 
Pain: Change in pain score (follow up: 2 years; assessed with: WOMAC – Pain Subscale; Scale from: 0 (less pain) to 100 (more pain)) 
1 Case series not serious N/A  
(only one trial) 
not serious serious 1 none 17 - - Mean reduction in pain 
was was 5.1 
(Pre-op: 91.0 ± 5.7 vs 
Post-op: 96.1 ± 4.6, 
p=0.002) 
⨁⨀⨀⨀ 
VERY LOW 
Pain: Change in pain score (follow up: 2 years; assessed with: Modified Cincinnati knee rating score; Scale from: 0 (less pain) to 100 (more pain)) 
1 Case series not serious N/A  
(only one trial) 
not serious serious 1 none 23 - - Mean reduction in pain 
was 10.6 
(Pre-op: 21.9 vs Post-op: 
32.5, p<0.03) 
⨁⨀⨀⨀ 
VERY LOW 
Function: Change in function score (follow up: 2 years; assessed with: FAAM; Scale from: 0 (worse function) to 100 (better function)) 
2 Case series not serious not serious not serious serious 1 none 57 - - Mean increase in 
function ranged from 
16.5 to 17 
(p<0.03) 
⨁⨀⨀⨀ 
VERY LOW 
Function: Change in function score (follow up: 2 years; assessed with: WOMAC – Function Subscale; Scale from: 0 (worse function) to 100 (better function)) 
1 Case series not serious N/A  
(only one trial) 
not serious serious 1 none 17 - - Mean increase in 
function was 15 
(Pre-op: 68.1 ± 23.8 vs. 
Post-op: 83.1 ± 20.4, 
p=0.03) 
⨁⨀⨀⨀ 
VERY LOW 
Function: Change in function score (follow up: 2 years; assessed with: WOMAC – Overall; Scale from: 0 (worse function) to 100 (better function)) 
1 Case series not serious N/A  
(only one trial) 
not serious serious 1 none 17 - - Mean increase in 
function was 17.2 
(Pre-op: 65.1 ± 24.8 vs. 
Post-op: 82.3 ± 19.9, 
p=0.02) 
⨁⨀⨀⨀ 
VERY LOW 
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Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies Study design Risk of bias Inconsistency Indirectness Imprecision 
Other  
considerations OCA 
Other surgical 
procedure 
Relative  
(95% CI) 
Absolute  
(95% CI) 
Function: Change in function score  
(follow up: 1.9 to 4 years; assessed with: Modified Cincinnati Knee Rating Score – Function Subscale; Scale from: 0 (worse function) to 100 (better function)) 
1 Case series not serious N/A  
(only one trial) 
not serious serious 1 none 23 - - Mean infcrease in 
function was 9.2 
(Pre-op: 27.3 vs Post-op: 
36.5, p<0.01) 
⨁⨀⨀⨀ 
VERY LOW 
Function: Change in function score  
(follow up: 1.9 to 4 years; assessed with: Modified Cincinnati Knee Rating Score – Overall Score; Scale from: 0 (worse function) to 100 (better function)) 
1 Case series not serious N/A  
(only one trial) 
not serious serious 1 none 23 - - Mean increase in 
function was 19.8 
(Pre-op: 49.2 vs Post-op: 
69.0, p<0.02) 
⨁⨀⨀⨀ 
VERY LOW 
Return to activities of daily living (follow up: 2 years; assessed with KOOS activities of daily living sub-scale; Scale from 0 (worse) to 100 (better)) 
2 Case series not serious Not serious not serious serious 1 none 51 - - Mean increase ranged 
from 14 to 16.3 
(p=0.048, p=0.004) 
⨁⨀⨀⨀ 
VERY LOW 
Return to activities of daily living (follow up: 2 years; assessed with KOOS sports and recreation sub-scale; Scale from 0 (worse) to 100 (better)) 
2 Case series not serious Not serious not serious serious 1 none 51 - - Mean increase ranged 
from 20 to 33.2 
(p=0.005, p=0.002) 
⨁⨀⨀⨀ 
VERY LOW 
Function: Change in quality of life (follow up: 2 years; assessed with: KOOS – QoL Subscale; Scale from: 0 (worse WoL) to 100 (better QoL)) 
2 Case series not serious not serious not serious serious 1 none 51 - - Mean increase in 
quality of life ranged 
from 25 to 30.6 
(p<0.001) 
⨁⨀⨀⨀ 
VERY LOW 
Necessity of total joint replacement (follow-up: 0.3 to 14.5 years) 2 
2 Case series not serious not serious not serious Serious none 125 - - Overall 5.6% (7/125) ⨁⨀⨀⨀ 
VERY LOW 
Safety 
Procedure-related mortality (follow up: 0.3 to 14.5 years) 2 
4 Case series not serious not serious not serious not serious none 0/165 - - 0% ⨁⨁⨀⨀ 
LOW 
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Quality assessment 
Summary of findings 
Number of patients Effect 
Quality 
Number  
of studies Study design Risk of bias Inconsistency Indirectness Imprecision 
Other  
considerations OCA 
Other surgical 
procedure 
Relative  
(95% CI) 
Absolute  
(95% CI) 
Complications (follow up: 12 months) 
4 Case series serious 3 serious 4 not serious serious 1 none 21/165 - - Overall complications: 
12.7% 
(range 4.3%% to 26.5%) 
⨁⨀⨀⨀ 
VERY LOW 
Transplant failure (follow up: 2 years; assessed with: removal or replacement of the graft, or progression to arthroplasty) 2 
2 Case series serious 3 not serious not serious serious 1 none 4/51 - - Overall transplant 
failures: 7.8% 
(range 7.0% to 11.8%) 
⨁⨀⨀⨀ 
VERY LOW 
Re-admission (outcome not reported) 
- - - - - - - - - - - - 
Re-operation (Follow up: 2 years; assessed with: any follow-up procedure on the treated joint) 2 
4 Case series serious 3 not serious not serious serious 1 none 34/165 - - Overall re-operation 
rate: 20.6% 
(range 11.8% to 41.2%) 
⨁⨀⨀⨀ 
VERY LOW 
Abbreviations: CI = confidence interval, N/A = not applicable, OCA = osteochondral allograft transplantation. 
Comments: 
1 Sample was below the optimal information size. 
2 A very small proportion of patients in one study had follow-up less than 2 years. 
3 Follow-up length was insufficient to properly measure the outcome. 
4 Large degree of variation in reported adverse event rates across studies. 
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Applicability table 
Table A-7: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The target population for osteochondral allograft transplantation in clinical practice is patients  
with ostechondral defects who have failed conservative management or primary surgery; however, 
relevant data was only identified for knee and ankle joints. 
Ankle: the RCT explicitly states that patients must have failed non-operative treatment (and initial 
arthroscopic treatment if the lesion is <1.5cm2) to be eligible. The majority of ankles in the case-series 
(94.1%) had undergone at least one prior surgery.  
Knee: no included case-series specified failure of non-surgical or primary surgical approaches as an 
inclusion criteria. Where reported (or where possible to calculate) mean number of prior surgeries 
varied from 0.7 to 1.7. One case-series specified the grade of cartilage defect (Grade 4 ICRS) of 
included patients. 
Ostechondral defects are often trauma-induced and often appear following a sporting injury, 
suggesting that active, younger patients are at a heightened risk. The mean age of patients across 
included studies fell between 30.9 to 41.9 years.  
All lesions of the ankle in included studies were located on the talar or talar dome. Lesions of the  
knee were mostly located on the femoral condyle. A small percentage (17.6%) in one study were 
located on the lateral tibial plateau.  
Intervention The intervention of interest is fresh or delayed-fresh ostechondral allograft transplantation.  
Ankle 
Ankle transplants were performed under general anesthetic, and a thigh tourniquet was used. They 
were either press fit into the OLT site without internal fixation (randomised trial) or fixed with herbert 
screws or bioabsorbable pins (case-series). Weight-bearing commenced 6-12 weeks post-operatively.  
Grafts in the RCT were used within 7 days of their release. Graft storage time in the case-series is 
unclear. Neither study reported any concommitant interventions occuring. It is possible that none 
were performed. 
Knee 
Knee transplants were press-fit into the site. Only one study reported that fixation was required [61]. 
Post-surgical non weight-bearing periods varied from immediate weight bearing, to non weight-bearing 
periods for 8 weeks, to partial weight-bearing for 1 year.  
Three studies reported graft storage time, which ranged from 3 to 26 days. Only two studies explicitly 
reported concomittant interventions. It is unclear how reflective the concomitant interventions 
reported are of clincial practice.  
Comparators Typically, patients must have failed conservative management (or primary surgery) to be eligible  
for OCA thus the relevant comparators were identified as other surgical management options.  
The comparator used in the randomised trial (specifically for lesions of the ankle) was an ostechondral 
autograft plug. The autograft was harvested from patients’ own knees (the ipsilateral superolateral 
distal femoral condyle).  
This is one possible alternate surgical approach to treat lesions of the ankle however, others also exist 
(e.g. autologous chondrocyte implantation or mosaicplasty) [49]. 
No comparative data of OCA compared to relevant comparator to treat lesions of the knee  
were identified.  
The evidence available does not include sufficient comparision to (all) possible comparators available 
in a clinical setting. 
Outcomes Ankle 
The randomised trial reported pain and functionality outcomes. The exact timing of post-operative 
measures presented is unclear; results from last follow-up were considered (mean follow-up times were 
3.4 and 2.9). Two of the most important clinical outcomes/objectives of surgical treatment were captured 
however, necessity of total joint replacement is another crucial outcome that was not reported.  
It is possible that no cases occurred considering the limited follow-up.  
Adverse events were well-reflected in the RCT, subsequent procedures were well-reflected in both  
the RCT and the case-series, transplant failure was reported in the case-series.  
Osteochondral allograft transplantation for the knee (or other joints) 
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Outcomes 
(continuation) 
Knee 
The single-arms studies of knee patients reported to varying degrees some or all of the crucial/ 
important effectiveness outcomes using various, knee-specific measurement tools. Only two studies 
clearly presented outcome results taken 2-years post-operatively. A third presented results from last 
follow-up (mean follow-up time was 3 years). Relevant outcomes presented by the final study were 
sparse; pertaining to adverse events, necessity of total knee arthroscopy and subsequent procedures.  
Overall, transplant failure rates and subsequent/revision surgeries were captured. Only one of the 
case-series specifed that complications were monitored – it is possible that adverse events were not 
adequately reported, given the reliance on patient reporting at follow-up appointments.  
Setting The included randomised study was conducted in a single centre in the USA. The included case series 
(included for both effectiveness and safety outcomes in knee patients, and safety outcomes 
exclusively for ankle patients) were conducted in single centres in either the USA or Canada.  
The settings of the studies reflect the clinical setting in which the technology is intended to be used in 
an appropriate way. No applicability issues are expected from the geographical setting. 
Abbreviations: ICRS = International Cartilage Repair Society, OCA = osteochondral allograft transplantation,  
OLT = osteochondral lesions of the talus, RCT = randomised controlled trial. 
 
 
List of ongoing trials 
Table A-8: List of ongoing trials of osteochondral allograft transplantation 
Identifier/ 
Trial name 
Patient 
population Intervention Comparison Primary Outcome 
Primary 
completio
n date Sponsor 
NCT00263432 
* unkown 
status 
Cartilage injury 
of the knee 
18-65 years 
Enrollment: 10 
Fresh allogenic 
chondrocyte 
implant 
N/A Healing of the 
cartilage injuries 
July 2015 University 
Hospital, Ghent. 
University Ghent. 
NCT02430558 
* unkown 
status 
Knee osteo-
chondral lesions 
18-55 years 
Enrollment: 40 
Osteochondral 
allografts  
(OD-
PHOENIX2) 
N/A IKDC, KOOS 
Recellularisation and 
integration of tissue 
Decembe
r 2016 
TBF Genie 
Tissulaire 
NCT02503228 
* active, not 
recruiting 
Osteochondral 
Defect of the 
femoral condyle 
Female 
≥18 years 
Enrollment: 50 
Missouri 
Osteochondral 
Allograft 
Preservation 
System  
-Preserved 
Cartilage 
N/A IKDC 
Tegner Activity Scale 
Patient-Reported 
Outcomes 
Measurement 
Information System 
survey 
Standard of Care 
Diagnostic Imaging 
Non-standard of 
care magnetic 
resonance imaging 
Blood and Urine 
Samples 
April 
2020 
University of 
Missouri-
Columbia| 
Musculoskeletal 
Transplant 
Foundation 
Abbreviations: IKDC = International Knee Documentation Committee,  
KOOS = Knee injury and Osteoarthritis Outcome Score, N/A = not applicable. 
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Literature search strategies 
Search strategy for CRD (DARE, NHS-EED, HTA) 
Search Date: 12/12/2018 
#1 MeSH DESCRIPTOR Cartilage, Articular EXPLODE ALL TREES 
#2 (osteochondral NEAR (defect* or injur* or lesion* or fracture* or rupture* or tear* or damage*)) 
#3 #1 OR #2 
#4 MeSH DESCRIPTOR Allografts EXPLODE ALL TREES 
#5 MeSH DESCRIPTOR Transplantation, Homologous EXPLODE ALL TREES 
#6 (allogeneic transplant*) 
#7 MeSH DESCRIPTOR CARTILAGE EXPLODE ALL TREES WITH QUALIFIER TR 
#8 MeSH DESCRIPTOR CHONDROCYTES EXPLODE ALL TREES WITH QUALIFIER TR 
#9 (allograft*) 
#10 (osteochondral) 
#11 (chondrocyt* NEAR (allograft* OR allogeneic)) 
#12 (OCA) 
#13 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
#14 #3 AND #13 
Total:36 Hits 
 
Search strategy for Ovid Medline 
Database: Ovid MEDLINE(R) <1946 to November Week 5 2018>, Ovid MEDLINE(R) Epub Ahead of Print 
<December 10, 2018>, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <December 206, 2018>, Ovid 
MEDLINE(R) Daily Update <December 06, 2018> 
Search Strategy: 
1 exp *Cartilage, Articular/in [injuries] (1744) 
2 (osteochondral adj5 (defect* or injur* or lesion* or fracture* or rupture* or tear*)).mp. (3473) 
3 1 or 2 (4901) 
4 exp Allografts/ (6271) 
5 exp Transplantation, Homologous/ (83779) 
6 allogeneic transplant*.mp. (4548) 
7 exp *CARTILAGE/tr [Transplantation] (4021) 
8 exp *CHONDROCYTES/tr [Transplantation] (1231) 
9 7 or 8 (5173) 
10 (allograft* or allogeneic).mp. (118237) 
11 9 and 10 (747) 
12 (osteochondral allograft* adj5 (transplant* or implant*)).mp. (275) 
13 OCA.ti,ab. (1003) 
14 (chondrocyt* adj5 (allograft* or allogeneic)).mp. (222) 
15 4 or 5 or 6 or 11 or 12 or 13 or 14 (92353) 
16 3 and 15 (291) 
17 remove duplicates from 16 (291) 
Search date: 11/12/2018 
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Search strategy for Embase 
No. Query Results Results Date 
#30 #12 AND #29 303 12 Dec 2018 
#29 #13 OR #14 OR #24 OR #25 OR #26 OR #27 OR #28 16,842 12 Dec 2018 
 'allotransplantation'/mj 5,112 12 Dec 2018 
#27 'allograft'/mj 9,421 12 Dec 2018 
#26 (chondrocyt* NEAR/5 (allograft* OR allogeneic)):ti,ab,de 382 12 Dec 2018 
#25 oca:ti,ab 1,502 12 Dec 2018 
#24 #18 AND #23 916 12 Dec 2018 
#23 #19 OR #20 OR #21 OR #22 212,883 12 Dec 2018 
#22 allograft*:ti,ab,de OR allogeneic:ti,ab,de 189,704 12 Dec 2018 
#21 (allogeneic NEAR/5 (transplant* OR implant*)):ti,ab,de 61,221 12 Dec 2018 
#20 'allotransplantation'/exp 35,376 12 Dec 2018 
#19 'allograft'/exp 38,789 12 Dec 2018 
#18 #15 OR #16 OR #17 5,271 12 Dec 2018 
#17 'chondrocyte* transplant*':ti,ab,de 689 12 Dec 2018 
#16 'cartilage transplantation'/exp 3,975 12 Dec 2018 
#15 'chondrocyte implantation'/exp 889 12 Dec 2018 
#14 ('osteochondral allograft*' NEAR/5 (transplant* OR implant*)):ti,ab,de 362 12 Dec 2018 
#13 'osteochondral allograft transplantation'/exp 59 12 Dec 2018 
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 4,435 12 Dec 2018 
#11 (osteochondral NEAR/5 (defect* OR injur* OR lesion* OR fracture* OR rupture* 
OR tear* OR damage* OR degenerat*)):ti,ab,de 
4,353 12 Dec 2018 
#10 'articular cartilage degeneration'/exp 13 12 Dec 2018 
#9 'articular cartilage damage'/exp 13 12 Dec 2018 
#8 'articular cartilage injury'/exp 24 12 Dec 2018 
#7 'articular cartilage defect'/exp 43 12 Dec 2018 
#6 'osteochondral fracture'/exp  82 12 Dec 2018 
#5 'osteochondral lesions of the talus'/exp 12 12 Dec 2018 
#4 'osteochondral lesion of the talus'/exp 52 12 Dec 2018 
#3 'osteochondral lesion'/exp 111 12 Dec 2018 
#2 'osteochondral injury'/exp 31 12 Dec 2018 
#1 'osteochondral defect'/exp 151 12 Dec 2018 
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Search strategy for The Cochrane Library 
Search Date: 12/12/2018 
ID Search 
#1 MeSH descriptor: [Cartilage, Articular] explode all trees and with qualifier(s): [injuries – IN] 
#2 ((osteochondral OR cartilage* OR chondrocyte*) NEAR (defect* OR injur* OR lesion* OR fracture* or 
rupture* or tear* OR damage*)) (word variations have been searched) 
#3 (osteochondral): ti,ab,kw (word variations have been searched) 
#4 (chondrocyte*): ti,ab,kw (word variations have been searched) 
#5 #1 OR #2 OR #3 OR #4 
#6 MeSH descriptor: [Allografts] explode all trees 
#7 (allograft*): ti,ab,kw (word variations have been searched) 
#8 (allgeneic): ti,ab,kw (word variations have been searched) 
#9 (“allogeneic transplant*”): ti,ab,kw (word variations have been searched) 
#10 (chondrocyt* NEAR (allograft* OR allogeneic)) (word variations have been searched) 
#11 MeSH descriptor: [chondrocytes] explode all trees and with qualifier(s): [transplantation – TR] 
#12 MeSH descriptor: [cartilage] explode all trees and with qualifier(s): [transplantation – TR] 
#13 MeSH descriptor: [Transplantation, Homologous] explode all trees 
#14 (osteochondral allograft* NEAR (transplant* or implant*)) (word variations have been searched) 
#15 (OCA): ti,ab,kw (word variations have been searched) 
#16 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR # 15 
#17 # 5 AND #16 
Total: 114 Hits 
 
 
 
  
 
